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Introduction: Gastric cancer is prevalent in the Western Cape region of South Africa and 
there is no suitable biochemical marker for pre-malignant disease. Previous work from our 
laboratory showed that a 55-65kDa glycoprotein associated with albumin, reproducibly 
fractionated with mucins from crude gastric mucus scrapings and gastric juice subjected to 
ultra-centrifugation in a caesium chloride density gradient. This protein was identified as α-1-
acid glycoprotein (AGP) by its protein spots on 2D-SDS-PAGE staining with Coomassie 
Blue. We sought to confirm the identification of the glycoprotein PAS spot and determine if 
AGP could be used as a clinical marker for pre-malignant gastric disease. We also 
determined the levels of MUC1, MUC4, MUC5AC and MUC6 in blood plasma and in gastric 
tissue (including MUC1c and MUC2), to ascertain if there was any correlation with the levels 
of AGP.  
Methods: Human gastric mucus scrapings were collected after total or partial gastrectomy 
from Groote Schuur Hospital. Briefly the mucus scrapes were collected into 5.0 ml of 6M 
guanidinium chloride containing 10mM EDTA, 5mM NEM and 1mM PMSF pH 6.5. After 
mucus purification by caesium chloride density gradient ultracentrifugation, glycoprotein 
identification was performed by Western blotting and staining with PAS. Samples which 
identified positive for glycoprotein were run on a 2D SDS-PAGE gel, stained with 
Coomassie Brilliant Blue then the spots of interest excised and run on a MALDI-TOF-TOF 
for identification.  
Blood samples were collected from patients 3 days after the gastrectomy (n=14). Normal 
blood was collected from volunteers (n=15). The concentration of AGP was determined with 
a human ELISA kit using the provided protocol. The levels of MUC1, MUC4, MUC5AC and 
MUC6 in the plasma were determined using a sandwich ELISA. Gastric tissue blocks were 
retrieved from the archives of the Division of Anatomical Pathology, National Health 
Laboratory Service, Groote Schuur Hospital. The expression of AGP and mucins, MUC1, 
MUC1core, MUC2, MUC4, MUC5AC and MUC6 were determined in the gastric tissue by 
immunohistochemistry techniques.  
Results: The PAS positive protein on both 1 and 2-D gels was identified as AGP. Levels of 
AGP in blood plasma were lower in cancer patients (336µg/ml) than that of healthy controls 
(547µg/ml) (p-value=0.00006). This was also observed in the adenocarcinoma tissue where 
the AGP expression was lower than normal gastric tissue. Cancer plasma levels were lower 
than controls for MUC1 (p=0.00017) and MUC5AC (p-value=0.02308). No difference was 
observed in MUC4 (p-value=0.343) and MUC6 (p-value=0.379) plasma levels between the 
two groups. Tissue staining of MUC1 and MUC4 did not correlate with ELISA findings but a 
correlation was observed with MUC5AC and MUC6. De novo MUC2 expression was 
observed in adenocarcinoma and intestinal metaplasia tissue.  
Summary: The lower levels of AGP-MUC1 combination in the blood of cancer patients 





I would like to extend my heartfelt gratitude and thanks to the following people for their 
contribution to my life and this thesis. 
Special thanks to you Mrs Marilyn Gale Tyler for the great help with immunohistochemistry 
and especially with the proof reading of my thesis. Your help over the whole course of my 
project has been tremendously valuable especially towards the end. Thank you for the advice 
both in lab work and in life.  
Thank you to Professor Dhiren Govender for your patience, kindness and taking the time to 
teach me about pathology and spark my interest. Thank you for your great assistance with my 
thesis and collecting tissue blocks for my project, it was truly invaluable. 
 Thank you to Professor Delawir Kahn for your advice, criticisms and encouragement. 
Special thanks to Professor Anwar Suleman Mall for being a great and inspiring supervisor. 
Thank you for always pushing me to do better and opening up my mind to the great and slimy 
world of mucins. Thank you for allowing me to be part of your lovely mucus family. 
Special thanks to Professor Bongani Ndimba, Rudo Ngara and Putuma Gqamana for the 
invaluable assistance with proteomics. Your support, advice and guidance throughout my 
project are truly appreciated. 
Thank you to Dr. Masheko Tetshedi for your assistance with sample collection. 
Special thanks to Associate Professor Eugenio Panieri, Senior Specialist Surgeon for valuable 
assistance with gastric specimen sample collection. Thanks to the D Floor Surgical Theatre 
staff at Groote Schuur Hospital for their help with the collection of gastric samples and 
patient handling.  
Thank you to Dr. William Horsnell and Erin Logan for their patience with my questions and 
great help with my ELISA protocol. 
Special thanks to you Mrs Zoe Elaine Lotz for your patience, everyday guidance and teaching 
over the course of my project. Thank you for all the generosity, kindness, advice and all the 
jokes to help encourage me. All your help is truly immeasurable.  
Thank you to Mrs Lizette Fick for all the encouragement, funny stories and great cake day 
experiments. 
Thank you to Mr Jason Lewis for the encouragement and the occasional dry joke to lighten 
the mood. Thank you also to Mrs Marita Mowers. 
Thank you to my lab-mates, Miss Refiloe Mofokeng, Mr Sam Pillay, Mr Baxolele Mhlekude, 
Miss Julia Peacocke and Mrs Yolanda Mthembu for the encouragement in panicked moments 
and the help with any issues that arose. I will always treasure the moments we shared.  
6 
 
Thank you to the secretaries in the Department of Surgery: Mrs Warda Brown, Mrs Michelle 
Ahsing, Mrs Brenda Fine, Mr Saadick Waggie and Mrs Yvette Wyngaard. 
Special thanks to the ladies in the Postgraduate Admission Office: Mrs Adri Winckler, Mrs 
Salega Tape and Mrs Jackie Cogill for their kindness and always opening their doors to assist 
me. 
Thank you to my family and friends for their never-ending support and always reminding me 
that the end was in sight. Thank you for inspiring me through your words and strengthening 
my belief in that I can achieve what I set my mind to.  
Lastly but most importantly, all praise and honour to God. Thank you for always guiding my 





















Table of Contents 
Abstract ............................................................................................................................................ 4 
Acknowledgements ........................................................................................................................... 5 
List of Figures .................................................................................................................................. 10 
List of Tables ................................................................................................................................... 13 
Abbreviations .................................................................................................................................. 14 
Chapter one - Introduction ............................................................................................................. 16 
Background ..................................................................................................................................... 16 
1.1 Mucus ....................................................................................................................................... 18 
1.12 Mucins ................................................................................................................................. 18 
1.13 Classification of mucins ........................................................................................................ 20 
1.13.1 Membrane-bound mucins ............................................................................................. 21 
1.13.2 Secreted (gel-forming) mucins....................................................................................... 21 
1.14 Synthesis of Mucins ............................................................................................................. 22 
1.14.1 Overall mucin synthesis ................................................................................................. 22 
1.14.2 O-glycans structures ...................................................................................................... 22 
1.15 Biochemical Structure of Mucin ........................................................................................... 24 
1.16 Mucin purification, proteolysis and reduction ...................................................................... 26 
1.2 Gastric mucus and mucins ......................................................................................................... 27 
1.21 Gastric mucus ...................................................................................................................... 27 
1.22 Gastric mucins ..................................................................................................................... 32 
1.23 Gastric mucin and H.pylori ................................................................................................... 33 
1.24 Tumour-associated antigens ................................................................................................ 34 
1.25 Mucin terminal glycans ........................................................................................................ 35 
1.3 Mucus and mucins in disease ..................................................................................................... 36 
1.31 Mucus in disease and previous work .................................................................................... 36 
1.32 Gastric Cancer ...................................................................................................................... 38 
1.3.2.1 Mucin Expression in Gastric cancer............................................................................... 39 
1.4 AGP ........................................................................................................................................... 40 
AIM: ................................................................................................................................................ 42 
OBJECTIVES: .................................................................................................................................... 42 
Chapter two - Materials and Methods ............................................................................................ 43 
2.1 Ethics ......................................................................................................................................... 43 
2.2 Materials ................................................................................................................................... 43 
8 
 
2.3 Methodology ............................................................................................................................. 46 
2.4 Patients ................................................................................................................................. 46 
2.5 Sample collection ............................................................................................................... 47 
2.6 Gastric scrape mucus purification....................................................................................... 47 
2.7 Analysis of fractions ........................................................................................................... 48 
2.8 1D SDS Polyacrylamide Gel Electrophoresis ........................................................................ 49 
2.9 2D Proteomics ................................................................................................................... 50 
2.10 2D SDS-PAGE .................................................................................................................... 51 
2.11 Enzyme-linked Immunosorbent Assay (ELISA) .................................................................. 53 
2.12 Histological studies .......................................................................................................... 55 
Results and Discussion ..................................................................................................................... 57 
Chapter three – Mucus purification and glycoprotein identification .............................................. 58 
3.1 Mucus purification ..................................................................................................................... 58 
3.2 Protein separation and glycoprotein staining ............................................................................. 60 
3.2.1 1D SDS-PAGE ...................................................................................................................... 60 
3.2.2 2D SDS-PAGE ...................................................................................................................... 61 
3.2.2.1 PAS staining of the 2D SDS-PAGE .................................................................................. 61 
3.2.2.2 Coomassie staining of the 2D SDS-PAGE ....................................................................... 63 
3.3 Glycoprotein Identification .................................................................................................... 67 
3.3.1 Spot Excision ................................................................................................................... 67 
3.3.2 Mass Spectrometry Analysis ............................................................................................ 67 
3.4 Discussion .............................................................................................................................. 72 
Chapter four - The development of an ELISA for AGP and mucin detection .................................... 74 
4.1 AGP Blood Plasma Concentration ........................................................................................... 74 
4.1.1 Healthy Patients compared to Cancer Patients ................................................................ 74 
4.2 Determination of Mucin Blood Plasma Levels......................................................................... 76 
4.3 MUC1 Blood Plasma Levels .................................................................................................... 76 
4.3.1 Healthy Controls compared to Cancer Patients................................................................ 76 
4.4 MUC4 Blood Plasma Levels .................................................................................................... 77 
4.4.1 Healthy Controls compared to Cancer Patients................................................................ 77 
4.5 MUC5AC Blood Plasma Levels ................................................................................................ 78 
4.5.1 Healthy Controls compared to Cancer Patients................................................................ 78 
4.6 MUC6 Blood Plasma Levels .................................................................................................... 79 
4.6.1 Cancer Patients compared to Healthy Controls................................................................ 79 
9 
 
4.7 Discussion .............................................................................................................................. 80 
Chapter five – Determination of protein expression in gastric tissue ............................................. 82 
5.1 Determination of Immunogenic score in Gastric Tissue using Immunohistochemistry ............ 82 
5.2 Protein Expression in Gastric Tissue ....................................................................................... 84 
5.2.1 AGP expression in gastric tissue ...................................................................................... 84 
5.2.2 MUC1 expression in gastric tissue ................................................................................... 86 
5.2.3 MUC1C expression in gastric tissue ................................................................................. 88 
5.2.4 MUC2 expression in gastric tissue ................................................................................... 90 
5.2.5 MUC4 expression in gastric tissue ................................................................................... 91 
5.2.6 MUC5AC expression in gastric tissue ............................................................................... 92 
5.2.7 MUC 6 expression in gastric tissue .................................................................................. 94 
5.3 Discussion .............................................................................................................................. 95 
Discussion, conclusion and future work .......................................................................................... 97 
Appendix ....................................................................................................................................... 101 
............................................................................................................................................................  
















List of Figures 
 
Figure 1.1: Schematic drawing showing the apoprotein with its tandem repeats and O-glycans 
attached to serine or threonine residues. The N-terminal is indicated by the blue and C-terminal 
indicated by the green where the non-PTS regions are located…………………………………….…19 
Figure 1.2: The core structures of the O-glycans which surround the apoprotein. Each core structure 
is built upon with either fucose, GalNAc, N-acetylglucosamine, N-acetylneuraminic acid or galactose 
...……………………………………………………………………........................................……….23 
Figure 1.3a: Proposed structure by Allen et. al for ‘Windmill’ model of mucin subunits. Four 
subunits linked by a linker protein…………………………………………………………….…...….25 
Figure 1.3b: Schematic of proposed structure by Carlstedt and Sheehan for linear flexible model of 
mucin glycoprotein. Subunits linked end to end via disulphide bridges……………………………...25 
Figure 1.4: A: shows the end to end disulphide bonds which form between the subunits. The 
formation of T-domains occurs after proteolytic attack of the non-glycosylated regions B: shows the 
subunits which are the products of reduction and form short strands with –SH bonds at each 
end…………………………………………………………………………………………………..…26 
Figure 1.5a: Full cross section schematic showing the areas and structures of the anatomy of the 
stomach …………………………………………………………………………………………..…...27 
Figure 1.5b: Schematic of layer of the inner gastric anatomy………………………………………..28 
Figure 1.5c: A schematic showing the distribution of cells and gel mucus layer which allows for the 
neutralisation of stomach acid and pepsin by HCO
3-
 retention………………………………………..28 
Figure 1.5d: Unstirred mucus layer which forms a gradient from the lumen (pH 1-2) to the epithelial 
cells (pH 7) which allows HCl neutralisation by HCO
3- 
to prevent gastric epithelial cells damage….29 
Figure 1.6: A: Rat mucosa of saline control group (undamaged), average mucosa thickness was 
70µm B: Ethanol exposed (damaged) mucosa layer, average of 20µm. C: Re-epithelialised mucosa 
exposed to ethanol then to saline solution was much thicker than the normal mucosa, average mucosa 
thickness of 680µm………………………………………………………………………………...….30 
Figure 1.7: Interaction between H. pylori and secreted and membrane bound mucin in the stomach. 
The bacterium competes between binding of both types of mucin……………………………………32 
Figure 1.8: The shortened oligosaccharides are shown where Tn is linked to GalNAcα via a Ser/Thr 
bond and becomes sialyl-Tn when sialic acid is added. The T antigen is not shown above and would 
have a galactose linking to GalNAcα. In a normal environment of biosynthesis these O-glycans would 
be converted to the core structures and be heavily glycosylated ..........………………………………33 
Figure 1.9: Sections of gastric tissue from normal, intestinal metaplasia and gastric cancer tissue 
stained with an antibody against alpha-1-acid glycoprotein which had been identified as the unknown 
protein of interest. A: Normal tissue (x40) showing dark staining therefore high expression in the 
parietal cells (indicated by the black arrows). B: Intestinal metaplasia (x40) showed higher expression 
than normal tissue with the cytoplasm of columnar cells. C: Intestinal type carcinoma (x40) showed 
11 
 
expression in the cytoplasm of the neoplastic glands. D: Diffuse type carcinoma (x20) showed 
expression in the cytoplasm of the neoplastic cells invading the stomach muscle wall………………36 
Figure 1.10: A schematic diagram of AGP showing the N-glycans attached to various carbohydrates 
in branched chains. These carbohydrates include sialic acid, galactose, fucose, mannose and N-
acetlyglucosamine. Sialyl Lewis
x 
shown by the dotted regions indicates a tumour antigen in gastric 
cancer………………………………………………………………………………………………….39 
Figure 3.1: Isopycnic ultracentrifugation profiles of gastric mucus 
purification.............................................................................................................................................58  
Figure 3.2: 1D SDS-PAGE of purified gastric mucins stained with PAS for glycoprotein 
identification..........................................................................................................................................59 
Figure 3.3: 2D SDS-PAGE of purified gastric mucins stained with PAS for glycoprotein 
identification..........................................................................................................................................61 
Figure 3.4a: 2D SDS-PAGE of purified gastric mucins stained with Coomassie Blue for protein 
identification in sample 4.......................................................................................................................63 
Figure 3.4b: 2D SDS-PAGE of purified gastric mucins stained with Coomassie Blue for protein 
identification in sample 9.......................................................................................................................64 
Figure 3.4c: 2D SDS-PAGE of purified gastric mucins stained with Coomassie Blue for protein 
identification in sample 10.....................................................................................................................65 
Figure 3.5: Mascot, a histogram of the probability based score results and protein sequence coverage 
for protein identification from sample 4................................................................................................68 
Figure 3.6: Mascot, a histogram of the probability based score results and protein sequence coverage 
for protein identification from sample 9................................................................................................69 
Figure 3.7: Mascot, a histogram of the probability based score results for protein identification from 
sample 10...............................................................................................................................................70 
Figure 4.1: Human blood plasma concentration of AGP of healthy controls and cancer patients.......74 
Figure 4.2: Human blood plasma levels of MUC1 of healthy controls and cancer patients................75 
Figure 4.3: Human blood plasma levels of MUC4 of healthy controls and cancer patients................76 
Figure 4.4: Human blood plasma levels of MUC5AC of healthy controls and cancer patients...........77 
Figure 4.5: Human blood plasma levels of MUC6 of healthy controls and cancer patients................78 
Figure 5.1: Immunohistochemical score showing differences in AGP and mucin expression in gastric 
tissue......................................................................................................................................................82 
Figure 5.2: Immunohistochemical AGP staining of three different sections of gastric tissue.............84 
Figure 5.3: Immunohistochemical MUC1 staining of three different sections of gastric tissue..........86 
Figure 5.4: Immunohistochemical MUC1c staining of three different sections of gastric tissue........88 
12 
 
Figure 5.5: Immunohistochemical MUC2 staining of three different sections of gastric tissue..........89 
Figure 5.6: Immunohistochemical MUC4 staining of three different sections of gastric tissue..........90 
Figure 5.7: Immunohistochemical MUC5AC staining of three different sections of gastric tissue.....92 


























List of Tables 
 
Table 1.1: Chromosomal loci of human mucin genes as listed in GenBank........................................20 
Table 2.1: Clinical and pathological data of patients in this study.......................................................45 
Table 2.2: Mucin antibodies used in ELISA.........................................................................................53 
Table 2.3: Antibodies and control tissues used in immunohistochemistry...........................................55 
Table 3.1: Summary of identified proteins from the SwissProt 2013_01 database using the Mascot 
search engine..........................................................................................................................................67 
























A405   absorbance at 405nm 
AMPS   ammonium persulphate 
CHAPS  3-((3-cholamidopropyl)-dimethyl-ammonio))-1-propanesulfonate 
CsCl   caesium chloride 
DAB   3,3’ -diaminobenzidine 
DMSO   di-methylsuphoxide  
DTT   dithiothreitol 
EDTA   ethylenediaminetetra-acetic acid  
ELISA   enzyme-linked immunosorbent assay 
GuHCl   guanidinium chloride 
HCC   hepatocellular carcinoma 
H&E   haematoxylin and eosin 
HID   high iron diamine 
HPLC   high-performance liquid chromatography  
HRPO   horse radish peroxidase  
H2O2   hydrogen peroxide  
H2SO4   sulphuric acid 
IAA   iodoacetamide 
IEF   isoelectric focusing  
IPG   immobiline pH gradient 
kDa   kilo-Dalton  
mA   milliamper 
MALDI-TOF  matrix assisted laser desorption ionization time of flight 
MS   mass spectrometry  
MUC   mucin 
15 
 
MW   molecular weight 
NEM   N-ethlymaleimide 
PAS   periodic acid Schiff 
PAS/AB  periodic acid Schiff/alcian blue 
PBS   phosphate buffered saline 
PMSF   phenylmethylsulfonyl fluoride 
rpm   revs per minutes 
SDS   sodium dodecyl sulphate 
SDS-PAGE  sodium dodecyl sulphate polyacrylamide-gel electrophoresis 
TEMED  N, N, N‘, N‘ – Tetramethylethylenediamine 
TMB   3,3‘,5,5‘-Tetramethylbenzidine 
Tween 20  polyoxyethylene sorbitan monolaurate 
VNTR   variable number of tandem repeats 
















Chapter one - Introduction 
Background 
 
There has been an increasing interest in mucins in the detection and treatment of carcinomas 
in general (Devine et al. 1992) and also in particular in their role as diagnostic and therapeutic 
agents (Graham et al. 1996). Tumour markers useful in diagnosing gastric carcinoma at an 
early stage have not been identified. Many of them, such as carcinoembryonic antigen are 
most often elevated in patients with incurable disease and are therefore not useful for early 
detection (Fuchs et al. 1995).  Hakkinen et al (Häkkinen et al. 1991) described a structure 
associated with gastric mucins in carcinoma that could be useful as a clinical marker, and 
Bara et al (Bara et al. 1988) showed that ovarian mucinous cysts contain common antigens 
with the mucous positive columnar epithelial cells of the normal gastric mucosa. Our lab has 
reported the fragmentation of MUC5AC, an epithelial gastric mucin that consistently 
generated a 55-65kDa glycoprotein in crude mucus scrapings and some gastric juice 
specimens from the stomachs of patients with ulceration, carcinoma or Menetrier’s disease. 
The data suggested this glycoprotein to be the response of the gastric mucosa to early injury 
in the form of inflammation, gastritis and intestinal metaplasia (Mall et al. 1999; Mall et al. 
2000; Mall et al. 2002). Other likely roles for this fragment suggested by mucinologists 
overseas were that it could act as an attachment factor for H. pylori (J Dekker, Amsterdam, 
personal communication) or a precursor of human gastric mucin (Klomp et al. 1994). Another 
possibility was that because of its N-linked (as opposed to its O-linked) glycosylation (Mall 
et al. 1999) , it could be similar to the MUC1 epitopes produced by mammary tumour cells, 
which acquire an N-linked glycosylation after normal cells become transformed (Hilkens et 
al. 1988). Previous studies from our laboratory (Mall et al. 1990; Mall et al. 1992) showed the 
55-65kDa fragment fractionated with albumin, raising the question of the incomplete 
purification of mucin from crude mucus secretions. However, albumin ‘contamination’ has 
more recently been experienced by other researchers (I Carlstedt, University of Lund, 
Sweden, personal communication and in plenary session of ICRF Mucus in Health and 
Disease Workshop, Cambridge UK, 2000). 
Nthato Chirwa raised a polyclonal antibody to AGP for his PhD (2008) entitled “The 
isolation, purification, tissue localization and identification of a glycoprotein found in the 
crude mucus gel of patients with carcinoma of the stomach” and published paper “A 40-
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50kDa glycoprotein associated with mucus is identified as α-1-acid glycoprotein in 
carcinoma of the stomach” (Chirwa et al. 2012). Using immunohistochemistry, Chirwa et al. 
(2012) showed that it was expressed in the parietal cells of the normal stomach and 
enterocytes of the small intestine. It was more highly expressed in diseases such as intestinal 
metaplasia and chronic gastritis and its highest expression was in the gastric tumour, 
explaining why it could be detected in crude mucus scrapings of patients with carcinoma of 
the stomach. AGP preservation from normal tissue through to pre-neoplastic changes to the 
formation of tumour is interestingly different to that of mucins, which are known to be down-
regulated in pre-malignancy. AGP stained for protein and carbohydrate on 2D gel-
electrophoresis and whilst the protein was identified, our researcher was unable to identify 
the glycosylated component of the protein because it was resistant to digestion with trypsin. 
These findings raise the question of AGP having potential as a marker for pre-malignancy or 
even a diagnostic and/or prognostic marker for stage of disease. The protein was identified by 
MALDI-TOF MS as α -1 acid glycoprotein (oroscomucoid), an immune suppressant in 
certain cancers (Chirwa et al. 2012). 
Gastric cancer is prevalent in the Western Cape region of South Africa and to date, there has 
not been a suitable biochemical marker for pre-malignant disease. New patients reporting to 
hospital present with pain and undergo endoscopy, followed by biopsy and histology to 
confirm diagnosis. In most instances, upon diagnosis of malignancy, it is too late to treat and 
surgery is performed to alleviate the condition. The five year survival figures for these 
patients are low. The development of a biochemical marker would be a significant 
contribution to the management and to the survival outlook of this disease. Thus our lab 
sought to determine whether α-1 acid glycoprotein will be a suitable clinical marker for early 












Mucus is a slimy thick substance secreted by cells located on epithelial surfaces throughout 
the gastrointestinal tract and acts as a medium for protection and lubrication of epithelial 
surfaces. It has antiprotease, antimicrobial and antioxidant properties which aid in its various 
functions (Voynow et al. 2009). It also prevents the auto-digestion of the stomach wall by 
hydrochloric acid which is produced by the parietal cells and helps moisten food as it travels 
down the oesophagus (Corfield et al. 2001). In the respiratory system, mucus acts as the first 
line of defence by trapping inhaled particles or pathogens (bacteria and viruses) and clears the 
respiratory mucosa via the action of microcilia (Thornton et al. 1997; Thornton et al. 2004). 
Mucus can also be found in the cervix where it protects the cervical epithelium from 
desiccation as well as regulating the activity of spermatozoa during the menstrual cycle 
(Carlstedt et al. 1983a).  
1.12 Mucins 
 





heavily O-glycosylated glycoproteins. The high level of glycosylation gives mucins their gel-
forming property (Jentoft 1990). There are two main types of mucin: monomeric mucins 
which are mostly located on the cell surface and oligomeric mucins which are secreted. 
Mucins have peptide sequences which contain tandem repeat regions. These sequences are 
enriched with serine, threonine and proline residues, known as PTS regions, and do not 
normally have cysteine residues. These PTS regions are normally long (up to 6000 amino 
acids) and usually make up more than half of the polypeptide (Dekker et al. 2002).  
Mucin molecules contain up to 80% carbohydrate in the form of acidic or neutral 
oligosaccharide units arranged linearly and in branched sequences (known as the bottle-brush 
model) (Thornton et al. 2004). The sugars are attached to the protein core (apoprotein) 
through oxygen linkages (O-linked glycosidic bonds). The oligosaccharide chain on a mucin 
consists of: N-acetylglucosamine, GalNAc, galactose, fucose and sialic acid where GalNAc 
normally attaches to the apoprotein via an O-linked glycosidic bond. Each of the branched 
chains has varying numbers of sugar residues where the terminal sugars are usually sialic 
acid, fucose, galactose esters and N-acetylglucosamine. The highly glycosylated regions are 
densely packed into globular structures and are interspaced with less glycosylated regions of 
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protein that are vulnerable to proteolytic degradation to form glycopeptides. The less 
glycosylated regions do not contain tandem repeats and are rich in charged amino acids. The 
N- and C-terminals of the polypeptides are non-PTS regions and usually encode for all the 
cysteine residues present in mucins (Dekker et al. 2002; Peppas et al. 2004).  
One mucin molecule has four subunits and each subunit is made up of a basic unit 
approximately 5 × 10
5
 in weight, consisting of one branched chain and one or two terminal 
peptide sequences. Individual mucin peptides are connected by intramolecular disulphide 
bonds which enables the reduction of mucins to form smaller subunits using reducing agents 
(Strous et al. 1992; MacAdam 1993; Gandhi et al. 1994; Fiebrig et al. 1995; Peppas et al. 
2004; Rose et al. 2006). Mucin molecules are joined together by intermolecular interactions 
that include hydrogen bonding, physical entanglements and hydrophobic interactions to form 
macromolecules (Creeth 1978; Sheehan et al. 1990; MacAdam 1993; Peppas et al. 2004). 
Figure 1.1 below shows a diagram of one mucin polypeptide. 
 
 
Figure 1.1: Schematic drawing showing the apoprotein with its tandem repeats (  ) and O-glycans 
attached to serine (  ) or threonine (  ) residues. The N-terminal is indicated by the blue and C-











1.13 Classification of mucins 
 
Mucin genes code for mucins according to their structure that can either be monomeric which 
produce membrane-bound mucins, or they can be oligomeric which form secreted or gel-
forming mucins. Table 1.1 shows all the MUC genes and their chromosomal location. 
 
 
MUC Gene Chromosome Locus 






























1.13.1 Membrane-bound mucins 
MUC1, MUC3A, MUC3B, MUC4, MUC11, MUC12, MUC13, MUC16, MUC17 and 
MUC20 are membrane bound mucins (Rose et al. 2006). They usually have a transmembrane 
domain, a sea-urchin-sperm-protein-enterokinase-agrin (SEA) domain and an epidermal-
growth-factor (EGF) domain. MUC3A, MUC3B and MUC12 are closely related as they are 
located on chromosomal locus 7q22 (Dekker et al. 2002). The main function of membrane-
bound mucins is to communicate extracellular information via intracellular signal 
transduction pathways. All membrane-bound mucins prevent cell surface proteolysis in 
addition to attacks from other cells. The mucin genes have cell or tissue specific expression 
but one tissue can express different types of mucins (Bansil et al. 2006; Rose et al. 2006). 
1.13.2 Secreted (gel-forming) mucins 
The secreted mucins include MUC2, MUC5AC, MUC5B, MUC6, MUC7, MUC8, MUC9 
and MUC19.  Secretory mucins are split up into two classes, gel-forming polymeric mucins 
and non-gel forming soluble mucins.  
The secreted and gel-forming polymeric mucins include MUC2, MUC5AC, MUC5B, MUC6 
and MUC19 and are all found at the chromosomal locus 11p15.5. These five mucins have 
homologous non-PTS regions and have von-Willebrand-factor like (vWF) domains and a 
conserved C-terminal domain (Dekker et al. 2002). The gel forming properties are linked to 
the cysteine rich domains within the C- and N-terminals that form polymers through 
disulphide bridges. These disulphide bridges are critical for mucus gel formation. 
The secreted and non-gel forming soluble mucins only include MUC7, MUC8 and MUC9. 
MUC7 is small but unlike the other secretory mucins, it does not contain cysteine-rich 
domains therefore does not form gels. MUC8 is a large mucin that does not have the vWF as 
well as the C1 and C2 domains on the C-terminal end of large mucins. All the secreted forms 
have a role in transport and also interact with membrane bound mucins through covalent and 






1.14 Synthesis of Mucins 
1.14.1 Overall mucin synthesis 
Mucin biosynthesis takes between 6-24 hours. The process begins firstly by transcription of 
the MUC gene in the nucleus and thereafter the transcript is transported to the endoplasmic 
reticulum where translation occurs. The MUC protein (apoprotein) is the first to be 
synthesised and then intramolecular disulphide bond formation occurs as well as N-
glycosylation. The start of O-glycosylation occurs in the cis-Golgi body and then the N-
acetylgalactosaminyl peptidyltransferase enzyme facilitates the transfer of N-
acetylgalactosamine (GalNAc) to the threonine or serine amino acids. The transfer of hexoses 
and hexosamines then occurs to each emerging O-glycan in a stepwise process by different 
glycosyltransferase enzymes (Kirnarsky et al. 1998). After post-translational modification, 
mucins are either stored in vesicles (granules) to be secreted (secretory mucins) or 
incorporated into the membrane (membrane-bound mucins) (Corfield et al. 2001; Rose et al. 
2006). 
1.14.2 O-glycans structures 
There are a number of core types of O-glycans that are attached to the apoprotein during 
mucin synthesis which make up a large part of the mucin molecule. These include GalNAc, 
N-acetylglucosamine, N-acetylneuraminic acid, fucose and galactose. Figure 1.2 shows the 
major core structures of O-glycans specifically found in mucins. Terminal sugars found on 
the O-glycans are important as they determine the biological and/or physical properties of 
mucins by their charge or hydrophobicity. Mucin terminal sugars are often altered in disease 















Figure 1.2: The core structures of the O-glycans which surround the apoprotein (            ). Each core 
structure is built upon with either fucose, GalNAc, N-acetylglucosamine, N-acetylneuraminic acid or 















1.15 Biochemical Structure of Mucin 
 
Mucin molecules have always been difficult to study due to their large bulky structure, 
heavily glycosylated regions and the dissimilarity between seemingly related mucins. Early 
mucus studies proposed two possible structures for the mucin subunits (shown below in 
Figure 1.3); the windmill or star form by Allen et. al (Allen et al. 1972) (Figure 1.3a), then 
the linear form by Carlstedt and Sheehan (Carlstedt et al. 1984) (Figure 1.3b). The windmill 
model was first supported by the susceptibility of mucin to the attack by thiols and proteases. 
Thereafter estimates of the native and reduced molecular weights of pig gastric mucin 
suggested the presence of four subunits (Allen et al. 1972). Analysis of amino acid end 
groups and the discovery of a 70,000 Mr linker protein also supported the windmill model for 
mucins (Pearson et al. 1981). Carlstedt and Sheehan’s results contradicted Allen’s results as 
they obtained mucin forms of much larger molecular weight found with pig gastric mucin 
(Carlstedt et al. 1984). Further support for the linear form was shown when nodule-like forms 
in linear chains were observed using electron microscopy. These chains were of varying 
lengths and more importantly, no branched forms were observed (Mantle et al. 1981; 
Carlstedt et al. 1983b; Sheehan et al. 1986; Peppas et al. 2004). Further work soon showed 
that the linear form was correct whereby mucin molecules formed flexible strands or subunits 
connected by disulphide bonds that ultimately formed an overall globular structure (Carlstedt 





Figure 1.3a: Proposed structure by Allen et. al for ‘Windmill’ model of mucin subunits. Four 
subunits linked by a linker protein. Reproduced from (Allen et al. 1972).  
 
Figure 1.3b: Schematic of proposed structure by Carlstedt and Sheehan for linear flexible model of 




1.16 Mucin purification, proteolysis and reduction 
As previously stated, mucus is a complex macromolecule and thus it is difficult to isolate, 
reduce and break down to its smaller subunits. Mucins are isolated by treatment with 6M 
guanidinium chloride (GuHCl) and protease inhibitors to protect the primary structure from 
degradation. Thereafter the mucins are purified by two rounds of caesium chloride (CsCl) 
isopycnic density gradient ultracentrifugation. The density for this purification is fixed at 
between 1.39 and 1.40g/ml. Proteolytic degradation occurs when enzymes target the 
accessible non-glycosylated regions of the protein core and form mucin monomers known as 
‘T-domains’. These monomers are end-to-end subunits connected and stabilised by folded 
intramolecular disulphide bonds (shown in Figure 1.4A). On the other hand when mucus is 
reduced with reducing agents such as dithiothreitol (1, 4-dithio-d-threitol) and 2-
mercaptoethanol (β-mercaptoethanol), approximately 600 nm length subunits form (shown in 
Figure 1.4B). The reduced subunits have unfolded disulphide bonds at each end (-SH bonds) 
and are referred to as ‘subunits’(Mantle et al. 1981). Figure 1.4 shows electron micrographs 
of the two structures that form after proteolysis and reduction. 
 
Figure 1.4: A: End to end disulphide bonds form between the subunits. The formation of T-domains 
occurs after proteolytic attack of the non-glycosylated regions B: Subunits which are the products of 





1.2 Gastric mucus and mucins 
1.21 Gastric mucus 
 
Figure 1.5a shows a schematic of the full stomach anatomy. Figure 1.5b shows a section from 
the wall of the stomach that has been magnified. This shows that the wall of the stomach has 
five layers which include from the lumen, the mucosa then the submucosa, the underlying 
muscle layer called the muscularis then the subserosa and the serosa. There is an upper loose 
layer of mucus which acts as a lubricant wall from the mechanical stresses that occur during 
digestion. The lower layer of mucus within the stomach forms a stable continual insoluble gel 
layer which has strong adhesion properties and thus adheres to the luminal surface of the 
gastric epithelium. Gastric mucus consists mainly of water then mucins, electrolytes, 
enzymes and other components such as bacteria and nucleic acids (Hotta 2000). Figure 1.5c 
shows the undisturbed layer of gastric mucus which allows for the retention of bicarbonate 
ions (HCO
3-
) secreted by the epithelial cells that neutralise some of the hydrochloric acid 
(HCl) and protects against pepsin proteolysis. The HCO
3-
 secretion is stimulated by the 
presence of acid in the stomach. The unstirred mucosal gel layer allows for a gradient to be 
formed from the luminal surface (acidic pH 1-2) to the epithelial surface (near neutral pH 7) 
so as to prevent damage to the epithelial cells shown in Figure 1.5d (Allen et al. 1979; Allen 
et al. 1984; Ichikawa et al. 2011). The overall efficiency of gastric protection by mucus is 
established by the thickness of the mucus layer which is determined by hormones, neural and 
paracrine stimulation (Taylor et al. 2000; Allen et al. 2005).  
 
Figure 1.5a: Full cross section schematic showing the areas and structures of the anatomy of the 




Figure 1.5b: Schematic of layer of the inner gastric anatomy(edoctoronline.com). 
 
 
Figure 1.5c: A schematic showing the distribution of cells and gel mucus layer which allows for the 
neutralisation of stomach acid and pepsin by HCO
3-





Figure 1.5d: Unstirred mucus layer which forms a gradient from the lumen (pH 1-2) to the epithelial 
cells (pH 7) which allows HCl neutralisation by HCO
3- 
to prevent gastric epithelial cells damage. 











The gastrointestinal tract has a mucus layer that protects against infection. In the stomach and 
large intestine there is a two-layered mucus gel that protects against infection and 
inflammation. This includes the inner stratified mucus layer and the outer mucus layer. The 
inner layer is 50-200µm in thickness and provides physical protection through the glycocalyx 
of the epithelial cells. The outer layer is less defined and is easily removed (Johansson et al. 
2011; Hansson 2012).  
Gastric mucus also acts to protect the lining of the stomach after injury to prevent further 
mucosal damage. Figure 1.6 shows the difference in the mucus layer thickness between the 
undamaged (Figure 1.6A), ethanol damaged (Figure 1.6B) and ethanol and saline damaged 
(Figure 1.6C) in a rat model. This work showed that after gastric epithelium was exposed to 
70% (v/v) ethanol and then to a saline solution, a mucus layer formed over the damaged 
epithelial cells. This mucosal layer was ten times thicker than the undamaged saline treated 
control group of gastric epithelial cells. (Sellers et al. 1987). Similar results are observed in 
human gastric tissue where the mucus gel of ulcerated tissue was five times thicker than that 




Figure 1.6: A: Rat mucosa of saline control group (undamaged), average mucosa thickness was 70μm 
B: Ethanol exposed (damaged) mucosa layer, average of 20μm. C: Re-epithelialised mucosa exposed 
to ethanol then to saline solution was much thicker than the normal mucosa, average mucosa 













1.22 Gastric mucins 
There are four mucins found within the gastric regions namely, MUC1, MUC4, MUC5AC 
and MUC6. There are a number of components which influence the behaviour of these 
mucins in the stomach such as the trefoil factors family (Sands et al. 1996; Thim et al. 2002), 
Helicobacter pylori (H.pylori) infection (Lindén et al. 2004), tumour-associated antigen 
(Corfield et al. 2000) and mucin terminal glycans (Corfield et al. 2001). These will b e 
discussed in a later chapter. 
MUC1 is a membrane-bound mucin located on chromosome 1q21-24. It has a cytoplasmic 
tail and extracellular domain. The mucin is located on the cell surface of epithelial cells and 
aids in protection by binding pathogens as well as functioning in intercellular cell signalling 
pathways. In solid tumours, a MUC1 variant is normally formed whereby the O-glycans are 
shortened and less branched (Taylor-Papadimitriou et al. 1999) . 
MUC4 is located on chromosome 3q29 and is expressed in the epithelium of the digestive 
tract. It provides protection and lubrication to epithelial surfaces. MUC4 consists of two sub-
units, the extracellular glycosylated MUC4-a and the transmembrane subunit with epidermal-
growth factor-like domains, MUC4-b. The extracellular subunit may have specific adhesive 
functions which could aid in metastasis when MUC4 expression changes in cancer, whereas 
the transmembrane subunit acts in cell signalling pathways. MUC4 has been implicated in 
pancreatic, lung and colon cancer but studies have not conclusively shown a change in 
expression in gastric cancer (Dekker et al. 2002). 
The MUC5AC gene is found on chromosome 11p15.5 and is highly expressed in gastric 
mucosa. MUC5AC, together with MUC6, are both key constituents of the protective layer 
covering the gastric epithelium, thus facilitating the formation of a pH gradient from the 
luminal surface to the epithelial surface as described earlier in chapter 1.12. It also protects 
against H.pylori as the O-glycans act as ligands for the bacteria.    
MUC6 is highly expressed in the gastric mucosa. It is located on chromosome 11p15.5 and it 
is about 24kb in length. MUC6 is located in the deep gland cells and is produced by the 
acinar cells of the duodenal Brüner’s glands. The glycans located on MUC6 have 
antimicrobial activity which aid in combating H.pylori. Some studies have found that 
shortened alleles of MUC6 are associated in H.pylori infection and gastric cancer (Corfield et 
al. 2000; Bansil et al. 2006).  
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1.23 Gastric mucin and H.pylori 
 
The stomach has a very hostile acidic environment in which most bacteria are unable to 
survive. Despite this, H.pylori is found in the stomach of 50% of the human population 
though the majority of them are asymptomatic. Infection with this bacterium is related to the 
development of gastric ulcers, gastritis and gastric adenocarcinoma and increases the risk of 
developing cancer by almost 3 times the normal amount.  
Mucins have the ability to bind bacteria by specific attachment sites through the presence of 
receptor analogue structures. Figure 1.7 shows the interaction between the bacteria and the 
gastric mucins. MUC5AC and MUC6 expression changes when H.pylori is present in the 
stomach. The MUC5AC receptor competes with the bacteria for binding sites on the 
epithelial surface. MUC6 carries a terminal α-1-4 linked N-acetylglucosamine residue that 
acts as an antibiotic against the bacteria (Zhang et al. 2001; Kawakubo et al. 2004). H.pylori 
causes a reduction in the renewal of the mucus layer but treatment of the infection results in 
the reversal of symptoms and the stomach goes back to its normal state (Corfield et al. 2000; 
Dekker et al. 2002; Lindén et al. 2004). 
 
Figure 1.7: Interaction between H. pylori and secreted MUC5AC and MUC6 in the stomach. 





1.24 Tumour-associated antigens 
 
When the gastric tissue is infected or diseased, for example, when it transforms to neoplastic 
tissue, mucin production is altered. Glycosylation of mucins is usually affected resulting in 
the expression of tumour-associated carbohydrate antigens which contribute to the 
pathogenesis of disease (Corfield et al. 2000) . These are made up of mucin-type 
carbohydrate antigens such as Tn, sialyl-Tn and T epitopes that form as a result of incomplete 
glycosylation which leads to production of short O-glycans shown in Figure 1.8 (Corfield et 
al. 2000).  
 
 
Figure 1.8: The shortened oligosaccharides are shown where Tn is linked to GalNAcα via a Ser/Thr 
bond and becomes sialyl-Tn when sialic acid is added. The T antigen is not shown above and would 
have a galactose linking to GalNAcα. In a normal environment of biosynthesis these O-glycans would 








1.25 Mucin terminal glycans 
 
Mucin terminal glycans are comprised of structures known as Lewis-type blood group 
antigens. These antigens are structurally related to determinants of the ABO blood group 




are found in 







 are co-localised with MUC5AC in the superficial 
cells. The over expression of these antigens
 
is common in gastric, lung, pancreatic and colon 






















1.3 Mucus and mucins in disease 
1.31 Mucus in disease and previous work 
 
Mucus plays a key role in protection of the gastrointestinal tract and changes in mucin 
expression are seen in a number of diseases such as intestinal metaplasia, gastric ulceration, 
H.pylori infection and inflammatory bowel disease. Some work has been done in our 
laboratory to evaluate mucin expression in gastric diseases such as Menetrier’s disease (Mall 
et al. 2003) and Pseudomyxoma peritonei (Mall et al. 2007; Mall et al. 2011) as mentioned 
earlier. Biochemical characterisation of gastric mucins from gastric cancer patients and 
patients with gastric ulcers showed that mucins from diseased stomachs were degraded. 
Gastric juices from these patients also showed a secreted 55-65 kDa glycoprotein with an 
unknown function (Mall et al. 1999). Important work has been done in our laboratory using a 
pig model investigating the effect of H. helimannii on mucosal changes using bile duct 
ligation. There was no association observed between infection with H. helimannii and the 
degradation of mucin (Mall et al. 2004). Further work has been done, again using the pig 
model with bile duct ligation to investigate changes in mucins caused by gastric ulceration. 
Purified mucins from pre-ulcerated and ulcerated stomachs had a degraded glycoprotein to 
total protein ratio that was higher as compared to normal stomachs. It was also found that 
purified mucin, GalNAc and fucose were decreased in the diseased stomachs (Mall et al. 
1997). The foundation of this project was laid when the unknown 55-65 kDa glycoprotein 
which consistently co-fractionated with mucins from gastric cancer and ulcerated stomachs 
was found to be N-linked using HPLC analysis (Mall et al. 1999). After this work the 
unknown glycoprotein was identified as alpha-1-acid glycoprotein (AGP) or orosomucoid 
and its expression in gastric tissue was determined using immunohistochemistry, the results 
of which are shown and summarised in Figure 1.9 (Chirwa et al. 2012). After observing the 
different levels of expression of AGP in the gastric tissue, this project sought to determine the 
levels of AGP in blood plasma from gastric cancer patients and normal controls and 




Figure 1.9: Sections of gastric tissue from normal, intestinal metaplasia and gastric cancer tissue 
stained with an antibody against alpha-1-acid glycoprotein which had been identified as the unknown 
protein of interest. A: Normal tissue (x40) showing dark staining therefore high expression in the 
parietal cells (indicated by the black arrows). B: Intestinal metaplasia (x40) showed high expression 
within the cytoplasm of columnar cells. C: Intestinal type carcinoma (x40) showed expression in the 
cytoplasm of the neoplastic glands. D: Diffuse type carcinoma (x20) showed expression in the 














1.32 Gastric Cancer 
In 2008, 12.7 million new cancer cases occurred worldwide with 7.8 million cancer deaths 
(Ferlay et al. 2010). A fair amount of these cases included gastric cancer (989,000 new cases 
in 2008) which is highly prevalent in the world and is the second leading cause of death as 
well as the fourth most common cancer in the world (Ferlay et al. 2010; Jemal et al. 2011). It 
is endemic in the Western Cape region of South Africa especially within the mixed 
(coloured) race population (Botha 1972; Bradshaw et al. 1985; Wyndham 1985). Gastric 
adenocarcinoma is the most common and makes up to 95% of gastric malignancies. Other 
types include primary gastric lymphoma which is the second most common, gastrointestinal 
lymphoma and carcinoids. Treatment methods include surgery, radiation and chemotherapy 
whereby the chance of survival decreases as the stage of the cancer increases (Lee et al. 
2010).  
The greatest risk factor for developing gastric adenocarcinoma is infection with H.pylori as it 
leads to inflammation and pre-neoplastic changes in the stomach wall. Other risk factors 
include stomach lymphoma, age (risk increases over 50), sex (more common in men), diet 
(risk increases with salty or smoked foods), tobacco use and obesity (Ferlay et al. 2010).  
Sufferers of gastric cancer are often asymptomatic in the early stages of the disease and many 
of the symptoms are similar to those caused by other infections and diseases therefore early 
diagnosis of the disease is difficult. Symptoms include lack of appetite, stomach pain, weight 
loss, abdominal discomfort, nausea, vomiting, heartburn, indigestion and swelling of the 
abdomen. 
Diagnosis is carried out by a number of tests with include upper endoscopy, upper 
gastrointestinal series, biopsy, endoscopic ultrasound, computed tomography, magnetic 
resonance imaging scans, positron emission tomography, chest X-rays, laparoscopy and 
laboratory tests which look for anaemia.  
There is a need for a new cost effective diagnostic test to be developed for gastric cancer that 
could be used in hospitals and clinics as well as aid in screening methods. In Western 
countries the 5-year survival rate is very low whereas in Japan studies show survival can 
increase more than 50% due to the implementation of population based screening (Fukao et 
al. 1995). South Africa could benefit from a cost effective blood test that could be readily 
distributed and easily used.  
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1.3.2.1 Mucin Expression in Gastric cancer 
Mucin expression has been shown to change as a result of gastric cancer. Normal MUC1 
levels decrease in cancer as MUC1 tends to form abnormal glycoforms which are thought to 
aid in neoplastic transformation and metastasis through growth factor receptors and signalling 
molecule interaction (Bafna et al. 2010). De novo MUC2 and MUC3 expression occurs 
within the stomach with intestinal metaplasia. MUC4 expression in gastric adenocarcinomas 
is similar to MUC1 where aberrant glycosylation occurs as well as upregulation of the mucin 
(López-Ferrer et al. 2000; Senapati et al. 2008). MUC5AC expression is related to tumour 
stage in gastric cancer whereby it decreases as the tumour advances. In intestinal metaplasia, 
MUC6 expression decreases whereas incomplete metaplasia has no expression. Expression of 
MUC6 is lower in intestinal-type gastric carcinomas than in adenomas. This suggests it may 



















Alpha-1-acid glycoprotein (AGP), also known as orosomucoid, is a 41-43kDa glycoprotein, a 
183 amino acid protein that functions against inflammation and makes up 1-3% of plasma 
proteins (0.4-1 mg/ml) (Imre et al. 2008; Tesseromatis et al. 2011). It has 45% carbohydrate 
content connected via five to six highly sialylated complex-type-N-linked glycans. Figure 
1.10, shows a schematic diagram of AGP which shows the branched sugar chains connected 
to the protein core. There are two to three main variants of AGP that are found in the blood 
plasma which are determined by the type of glycosylation and amino acid substitution that 




Figure 1.10: A schematic diagram of AGP showing the N-glycans attached to various carbohydrates 
in branched chains. These carbohydrates include sialic acid, galactose, fucose, mannose and N-
acetlyglucosamine. Sialyl Lewis
x 
shown by the dotted regions indicates a tumour antigen in gastric 
cancer. Reproduced from (Ryden 2002).  
41 
 
AGP is produced in the liver, secreted mostly by hepatocytes and is a member of the acute 
phase protein family. The plasma concentration of acute phase proteins increases greatly in 
response to systemic tissue injury, inflammation or infection (Fey et al. 1987). The increase 
in these proteins directly correlates with hepatic synthesis. AGP is largely involved in drug 
interactions (mainly basic drugs) by displacing drugs from their binding sites resulting in a 
pharmacokinetic response (Imre et al. 2008; Tesseromatis et al. 2011). Numerous studies 
have indicated that AGP may have diagnostic value. Plasma concentration of AGP is 
increased in breast, lung and ovarian cancer and it may have genetic variants that could be 
linked to each cancer. In hepatocellular carcinoma (HCC), levels of AGP have been shown to 
be higher compared to patients with chronic liver disease (Kim et al. 2006). AGP together 
with alpha-fetoprotein has a high sensitivity and accuracy in the diagnosis of HCC (Lee et al. 
2006a; Bachtiar et al. 2009). It is because of this as well as the previous findings in our 
laboratory that we therefore postulate that gastric cancer patient prognosis could be improved 
by developing a test in which the ratios of AGP and various mucins in plasma are compared 


















 To investigate the potential of α-1-acid glycoprotein (AGP) as a biomarker for pre-malignant 
changes in the gastric mucosa and to investigate whether AGP and mucin (MUC1, MUC4, 
MUC5AC and MUC6) in blood plasma concentrations differ in cancer and healthy controls.  
Objectives: 
(1). To confirm previous results from our laboratory (Chirwa et al, 2012) where 3 blue spots 
and one pink spot were observed by Coomassie Blue and PAS staining respectively, on SDS-
PAGE gels of mucins purified from crude gastric scrapings, by 2D gel electrophoresis.   
(2). To identify the glycosylated component that stained for PAS on the gels from 2D gel 
electrophoresis by MALDI TOF analysis.  
(3). To determine whether this marker (AGP) is present in blood by measuring its 
concentration using a commercial ELISA kit, comparing its levels in gastric cancer and 
healthy controls and relating its levels to stage of disease. 
(4). To compare the expression of the trans-membrane (MUC1 and MUC4) and gel-forming 
(MUC5AC and MUC6) gastric mucins in cancer of the stomach and in healthy controls. 
(5). To determine the expression of the abovementioned proteins including MUC1core and 







Chapter two - Materials and Methods 
2.1 Ethics 
The University of Cape Town Research Ethics Committee re-approved this study on the 28
th
 
of June 2012 (HREC REF: 226/2009). Recruited patients were required to sign a consent 
form to indicate that they understood their involvement in the project.  
2.2 Materials 
Gastric mucus purification:  
- GuHCl (Sigma-Aldrich) 
- CsCl (Sigma-Aldrich) 
- NEM (Sigma-Aldrich) 
- PMSF (Sigma-Aldrich) 
- EDTA (Merck) 
- Dialysis tubing (Sigma-Aldrich) 
- CHAPS (Sigma-Aldrich) 
- Schiff reagent 
- Period acid solution (Merck) 
- Bradford assay solution (BioRad) 
- 2-mercaptoethonol 
- DTT (Sigma-Aldrich) 
- IAA (Sigma-Aldrich) 
- Agarose 
- Poly-L-lysine (Sigma-Aldrich) 
- Nitrocellulose membrane (Whitehead Scientific) 
- AMPS (Sigma-Aldrich) 
- TEMED (Sigma-Aldrich) 
- 30% Bis/Acrylamide 
- Running gel buffer pH 8.8 
- Spacer gel buffer pH 6.8 
- ColorBurstTM Electrophoresis Marker (Sigma)  
- Ethanol (Kimix) 
- 3% Acetic acid 
- 0.1% Sodium metabisulphite in 10mM HCl (Merck) 
- SCC x4 
- Centrifuge tubes (Kimix) 
- Specimen jars (Kimix) 
- Freeze-dryer flasks (United Scientific) 
- Polyclonal AGP (Abcam) 
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2D SDS-PAGE Electrophoresis: 
- Coomassie Brilliant blue 
- Acetone 




- Bromophenol blue 
- Mineral oil 
- IPG strips (BioRad) 
- Precast gels (Vacutec) 
- PageRulerTM Unstained Protein Ladder (Thermo Scientific) 
 
Histochemistry and Immunohistochemistry: 
- Formalin 
- Xylol (Kimix) 
- Absolute alcohol (Kimix) 
- Haematoxylin (Merck) 
- Scotts water  
- 1% Eosin (Merck) 
- Entellan (Merck) 
- High iron diamine solution (Merck) 
- 1% Alcian blue (Sigma-Aldrich) 
- Acetone 
- 1% Hydrogen peroxide 
- Citrate buffer pH 6 
- Normal goat serum (Dako) 
- Polyclonal AGP (Abcam) 
- Monoclonal MUC1 (Novocastra) 
- Monoclonal MUC1core (Novocastra) 
- Monoclonal MUC2 (Novocastra) 
- Monoclonal MUC4 (Santa-Cruz) 
- Monoclonal MUC5AC (Novocastra) 
- Monoclonal MUC6 (Novocastra) 
- Secondary antibody Envision monoclonal anti-mouse 
(Dako) 
- Secondary antibody Envision polyclonal anti-rabbit (Dako) 
- DAB (Dako) 
- 1% Copper sulphate 
- Coverslips (Lasec) 
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ELISA Assay:  
- AGP Human ELISA kit (Abcam) 
- MUC1 antibody (Abcam) 
- MUC4 antibody (Abnova) 
- MUC5AC antibody (Abcam) 
- MUC6 antibody (Novus Biologicals) 
- Polyclonal anti-mouse antibody (HRPO-linked) (Dako) 
- Polyclonal anti-rabbit antibody (HRPO-linked) (Dako) 
- PBS  
- PBS with 0.5% Tween (PBST) 
- 0.5% milk in PBS 
- 1% TMB in DMSO (Merck) 
- Citrate buffer pH 6 
- 30% Hydrogen peroxide (Kimix) 
- 2.5M Sulphuric acid 



















Mucus scrapes (n=10) and blood samples (n=14) were obtained from patients who underwent 
a partial or total resection for malignant gastric disease. These patients were from Groote 
Schuur Hospital and the University of Cape Town Private Academic Hospital. The patient’s 









2 55 M Metastasis  Gastric 
adenocarcinoma 
Stage IV Stenting GSH 








Stage I Partial 
gastrectomy 
GSH 
4 79 M Metastasis Gastric 
intestinal 
adenocarcinoma 











Stage IV Unresectable GSH 





Stage IV Unresectable, 
Stenting 
GSH 





Stage IV Stenting GSH 





Stage IV Unresectable, 
Stenting 
GSH 








Stage IV Unresectable, 
Stenting. 
GSH 




Stage I Partial 
gastrectomy 
GSH 
Files from patients 1, 9-11 and 14 were not available (UCT Private and GSH).  
Table 2.1: Clinical and pathological data of patients in this study. 
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2.5 Sample collection 
2.51 Crude mucus scrapings 
Total or partial gastrectomy samples (n=10) were provided shortly after resection by a 
surgeon. A small cut was made along the greater curvature of the stomach to expose the inner 
mucosal lining. Two sterile glass slides were used to gently scrape off the mucus from the 
mucosa into containers with 6M guanidinium chloride and a cocktail of protease inhibitors, 
namely, 5mM NEM, 10mM EDTA and 1mM PMSF pH 6.5. The samples were transported 
on ice and stored at -20°C until required. 
2.52 Blood sample collection 
Blood samples were taken from patients three days after surgery (n=14) by an intern. Normal 
blood was collected from volunteers by Dr Masheko Tetshedi, a qualified physician (n=15). 
The samples were collected into heparin tubes and spun at 3 000 rpm for 15 minutes at 4°C to 
separate the plasma from the blood cells. The plasma was then stored at -20°C until further 
examination.  
2.53 Gastric tissue block collection 
Tissue blocks that had been fixed with formalin and embedded with wax were obtained from 
the archives of the Division of Anatomical Pathology, National Health Laboratory Service, 
Groote Schuur Hospital. Professor D. Govender (pathologist) assisted in finding and 
collecting the available blocks (n=4) and in the assessment of the histochemistry and 
immunohistochemistry techniques. 
2.6 Gastric scrape mucus purification 
Crude mucus was stirred overnight at 4°C to solubilize the material. Samples were then 
homogenized, using a Junkel and Kunkel Ultra-Turrax by slowly increasing the revolutions 
from 8 000 rpm to 9 500 rpm at room temperature, to increase the solubility of the mucus for 
30 seconds. The insoluble debris was removed by centrifugation at 3 000 rpm for 60 minutes 
at 4°C. The soluble mucus material was adjusted with 4M GuHCl and solid CsCl to a density 
of 1.39-1.40 g/ml (Creeth et al. 1970). Each sample was pipetted into a Beckman 
ultracentrifuge tube using a glass pasteur pipette and sealed using a Beckman tube topper. 
Isopycnic density gradient ultracentrifugation was performed for 48 hours at 40 000 rpm at 
4°C (Beckman L45 centrifuge). The samples were divided into nine equal fractions and the 
density, protein and glycoprotein content of each fraction was determined. Each fraction was 
dialysed against distilled water three times over 24 hours at 4°C to remove CsCl and GuHCl. 
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The PAS positive glycoprotein fractions were pooled and subjected to a second isopycnic 
density ultracentrifugation and each fraction was assessed for density, protein and 
glycoprotein. The fractions with purified mucins (glycoprotein peak and density of 1.39-1.40 
g/ml) for each sample were pooled, dialysed against 3 changes of distilled water and then 
freeze dried.  
2.7 Analysis of fractions 
2.71 Dialysis 
The cellulose membrane dialysis tubing (Sigma-Aldrich Steinheim, Germany) was prepared 
by boiling in distilled water with 0.5% sodium bicarbonate/EDTA for 1 minute. Each fraction 
was then dialysed over 24 hours against three changes of distilled water. This was done to 
remove the GuHCl and the caesium chloride salts from the fractions.   
2.72 Density determination 
The density was determined by measuring the weight of 1.0 ml of each sample fraction 
against the weight of 1.0 ml of distilled water. 
2.73 Protein content  
The protein content was determined using the Bradford assay method (Bradford 1976) at an 
absorbance wavelength of 595nm using an Anthos htll Spectrophotometer, Austria.  
2.74 Glycoprotein content 
The periodic acid Schiff assay was used to measure the glycoprotein content (Mantle et al. 
1978). Schiff reagent was decolourised by the addition of sodium metabisulphite and 
incubation in a water bath at 37°C for 1 hour. This was added to the sample after oxidation 
with periodic acid and then incubated for 30 minutes. The absorbance was read at 585nm.  
2.75 Freeze drying 
After dialysis, the samples were placed into containers with numerous smalls holes on the 
lids. Thereafter they were either frozen in a BIOVAC Ultra Low Freezer at -86°C or flash 
frozen in liquid nitrogen then transferred into Virtis vacuum flasks. These flasks were then 
connected to the freeze dryer (Christ Alpha I-5, Lasec) and the samples were left to freeze 
dry. The flasks were checked frequently to ensure the samples were not thawing as this would 





2.8 1D SDS Polyacrylamide Gel Electrophoresis 
The samples were reduced with 10mM DTT in 10mM PBS pH 6.5 and incubated in a 37°C 
water bath for 5 hours. The sulphate bonds were alkylated by the addition of 2.5mM of IAA 
per sample and left in the dark overnight.  
The reduced and alkylated sample was diluted with sample application buffer containing 
0.01% bromophenol blue, 2% sodium dodecyl sulphate, 10% glycerol and 0.2M 2-
mercaptoethonol. The samples were boiled for 2 minutes, 15-20µg was loaded on a SDS-
PAGE gel (7.5% running gel and 3.0% spacer gel) and run at 20mA per gel at 400V for 
approximately 2 hours on the Vacutec gel dock apparatus using the Laemmli method 
(Laemmli 1970). A molecular weight marker was included. 
2.8.1 PAS Gel Staining 
After electrophoresis, the gel was stained with PAS according to the method of Dubray and 
Bezard. Gel fixation in 50% ethanol then oxidation in 1% periodic acid in 3% acetic acid was 
performed. Thereafter the gel was stained with Schiff reagent in the dark and destained with 
















2.9 2D Proteomics 
2.9.1 Sample protein precipitation and preparation 
The gastric mucus scrapes that had a positive pink spot on the 1D SDS-PAGE where chosen 
for 2D electrophoresis. Five mg of each sample was dissolved in 2.0 ml of PBS and the 
proteins were precipitated using four volumes (8.0 ml) of acetone. The samples were left 
overnight at -20°C then spun at 3 000 rpm at 4°C for 15 minutes. The supernatant was 
removed and the pellet resuspended in 8M urea buffer at room temperature. A Bradford assay 
was performed with protocol described earlier in section 2.73. The volume equivalent to 
100µg was calculated for each sample.  
2.9.2 Reswelling/Rehydrating the IPG strips 
To each sample 50% DTT then 1.25µl ampholytes was added and made up to a volume of 
125µl with 8M urea buffer. Bromophenol blue was added to the sample and centrifuged. The 
reswelling tray was balanced on a level surface then each sample was added into a separate 
tray lane.  The immobiline pH gradient (IPG) strips (7cm, pH 3-10, BIO-RAD) were 
removed from the fridge and the gel was carefully separated from the cover slip. Each gel 
was then placed on the sample with the gel side facing downwards. Care was taken not to trap 
bubbles under the gel strip. Drystrip Cover Fluid (GE Healthcare) mineral oil was poured into 
each lane to ensure the gel strip did not dry out. The samples were left to reswell overnight at 
room temperature. 
2.9.3 Isoelectric focusing of the IPG strips 
After rehydration, the strips were rinsed in distilled water to remove excess urea buffer which 
can cause bad resolution on the gels as well as increase the time of isoelectric focussing (IEF) 





 IEF machine, GE Healthcare, Amersham, UK), gel side facing 
upwards with 1.5cm wicks at either end of each strip covering a small portion of the gel. The 
electrodes were placed on the wick and thereafter each lane was covered with mineral oil. 
The machine was then run in a step wise programme with the following settings for 
approximately 6 hours at 20°C: Step 1 – 250V for 15 minutes; Step 2 – 4 000V for 1 hour; 






2.10 2D SDS-PAGE 
 
After IEF, the strips were washed with distilled water and blotted on wet filter paper. The 
strips were equilibrated by incubating them in an SDS buffer (6M urea, 2% SDS, 50mM 
Tris/HCl pH 8.8 and 20% glycerol) containing 2% DTT for 15 minutes on a shaker. 
Following this, the strips were treated with SDS buffer containing 2.5% iodoacetamide in 
place of DTT. The strips were then washed with 1 x SDS-PAGE running buffer to aid in the 
transfer of proteins from the IPG strips to the SDS-PAGE. The strips were then loaded onto a 
pre-cast 12% SDS-PAGE. A marker was added to each gel on a dried 0.5cm wick then the 
strips were sealed with 0.5% agarose which solidified before beginning the electrophoresis. 
The gels were run at 130V for approximately 75 minutes at room temperature until the dye 
had reached the bottom of the plates. The gels were stained with PAS (described previously) 
and Coomasssie Brilliant Blue to visualise the protein spots. 
2.10.1 Coomassie Brilliant Blue R-250 gel staining 
After gel electrophoresis, the gels were stained with Coomassie solution 1 (10% glacial acetic 
acid, 2% Coomassie stock, 25% propan-2-ol) for 30 minutes after heating in the microwave 
for approximately 1 minute. This was repeated with Coomassie solution 2 (10% glacial acetic 
acid, 0.25% Coomassie stock, 10% propan-2-ol) and Coomassie solution 3 (10% glacial 
acetic acid and 0.25% Coomassie stock). Thereafter the gels were destained in destaining 
solution (10% glacial acetic acid, 1% glycerol in water) until the protein spots become 
visible. 
2.10.2 Protein spot identification 
The target protein spots were identified according to size using the molecular weight marker 
and the corresponding PAS staining as reference. Each spot was excised with a clean tip and 
sent for identification using MALDI-TOF-TOF mass spectrometry. Briefly: The spot was 
excised then underwent reduction with 50mM DTT then alkylation with 50mM IAA. The 
reduced and alkylated spot was then digested with Trypsin Gold (Promega, Madison USA) at 
37°C for 15 hours. Then 8µl 10% trifluoroacetic acid (TFA) was added to the digested spot 
and transferred to 4°C to stop the digestion and stored at -20°C until needed. The digests 
were extracted from the gel and analysed on the UltrafleXtreme MALDI-TOF-TOF mass 
spectrometer (Bruker, Bremen) using a matrix (alpha-cyano-4-hydroxy-cinnamic acid, 
CHCA) mixed on a prespotted PAC-II 386 spot target plate (Bruker). The AutofleX script 
was executed to run MS and tandem MS in reflectron mode where the top 50 precursor 
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peptide ions were selected from the spectra. Laser-induced fragmentation was then used for 
further sequencing to generate MS/MS spectra. For peptide identification, the MS/MS spectra 
corresponding to each sequenced precursor ion of given m/z value was searched for on the 
Mascot search engine in the Bruker ProteinScrape server. This was searched against in-silico 
MS/MS spectra generated using the Swissprot 2013_01 database. Spectra to peptide matches 
were produced on the basis of the search parameters for our protein of interest which 
























2.11 Enzyme-linked Immunosorbent Assay (ELISA) 
 
For the quantitative measurement of human AGP concentrations in plasma from normal 
healthy individuals and cancer patients (done in duplicate), an alpha-1-acid glycoprotein 
Human ELISA kit (abcam) was used. The AGP concentrations were determined using the 
protocol from the kit and read from the standard curve generated by using the standard 
provided. Statistical analysis was performed using the StatPlus package from Analystsoft. 
Standard deviations were calculated as for a sample population. 
For semi-quantitative measurement of the mucins, a sandwich ELISA was used with plasma 
samples from healthy individuals and cancer patients. The target antigens were MUC1, 
MUC4, MUC5AC and MUC6 and the respective antibodies were used. The ELISA was 
optimised with the following parameters: pH of the carbonate coating buffer, concentration of 
the primary antibody and the concentration of the antigen. After optimisation, the primary 
antibody for each antigen was diluted at the optimal concentration (shown in Table 2.2) and 
incubated overnight at 4°C in a 96-well plate and the contents discarded. Next, blocking 
buffer (0.5% gelatine in PBS) was added to each well to minimise non-specific binding, the 
plate was sealed and incubated at room temperature for 4 hours. The well contents were 
discarded and the plasma from each patient was then added to the 96-well plate in triplicate. 
The plasma samples for MUC1, MUC4, MUC5AC and MUC6 were diluted in PBST with 
0.1% gelatine at concentrations of 1:200, 1:500, 1:200 and 1: 200 respectively. The plate was 
then incubated overnight at 4°C. The unbound sample was discarded and thereafter each well 
was washed with washing buffer (PBST with 0.1% gelatine) three times. Detection was 
performed with a secondary antibody (HRP antibody) which bound to the antigen. The 
secondary antibody was diluted according to the manufacturer’s protocol and added to each 
well. After 2 hours incubation at room temperature, the well contents were discarded, washed 
again with PBST and working substrate solution (1% TMB in DMSO, citrate buffer pH 6.0 
and 30% H2O2) added to each well for 20 minutes at 37°C. The colour reaction was stopped 







Antibody Antigen Concentration 
Mouse monoclonal MUC1 
(Abcam) 
Peptide epitope RPAP within 
protein core 
1:100 
Mouse monoclonal MUC4 
(Abnova) 
Partial recombinant protein of 
MUC4 
10µg/100µl 
Mouse monoclonal MUC5AC 
(Abcam) 
Human MUC5AC  1:100 
Rabbit polyclonal MUC6 
(Novus Biologicals) 

























2.12 Histological studies 
2.12.1 Sample preparation 
Gastric tissue blocks from patients who had a gastrectomy were retrieved from the archives 
of the Division of Anatomical Pathology, National Health Laboratory Service, Groote Schuur 
Hospital. The gastric tissue was formalin fixed and paraffin wax embedded. Two µm sections 
were cut using a microtome (Leica SM 2000 R, Germany). The sections were mounted onto 
glass slides for histochemistry and amino-propyl-tri-ethoxy-silane (APES) slides for 
immunohistochemistry. Positive and negative tissue controls were cut for each antigen as 
well as normal gastric tissue. The slides were incubated at 55°C for 40 minutes then left at 
room temperature until staining.  
2.12.2 Histochemistry 
The section from each patient was stained with haematoxylin and eosin (H&E) which shows 
morphology, determining diagnosis. Sections were stained with periodic acid Schiff/alcian 
blue (pH 2.5) (PAS/AB) to identify acidic (blue) and neutral (pink) mucins. Sections were 
also stained with high iron diamine/alcian blue (HID/AB) which stains sulfomucins (black) 
and sialomucins (blue). The protocols described in Bancroft and Gamble 2008 were followed 
for the H&E and PAS/AB stain and Spicer 1965 for HID/AB staining. 
2.12.3 Immunohistochemistry 
 A general protocol was followed where each tissue sample available was tested once for 
each antigen but different incubation times were used for the primary antibody depending on 
the antigen. The sections were dewaxed in three changes of xylol for 5 minutes each, and 
then rehydrated through decreasing graded alcohols for 2 minutes each. After rinsing in 
water, the slides were incubated at room temperature in 1% H2O2 for 15 minutes to block 
endogenous peroxidise activity. Following this, heat-mediated antigen retrieval was 
performed in citrate buffer (0.01M, pH 6.0) in a pressure cooker (Amalgamated Appliances 
Holdings, Reuven, South Africa) for 2 minutes at full pressure. The slides were then cooled 
in running tap water for 10 minutes then rinsed with PBST. Next blocking was performed 
using normal goat serum in PBS for 10 minutes (1:20) to prevent non-specific binding. A 
negative control was added replacing the primary antibody with PBS. The primary antibody 
diluted in PBS was added to the slides. The concentration of the primary antibodies and the 
varying incubation times as well as the relevant positive control tissue is shown in Table 2.3. 
After incubation, each slide was washed with PBST then incubated with secondary antibody 
(Envision), either anti-mouse or anti-rabbit depending on the primary antibody, for 30 
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minutes. After rinsing the colour was developed with DAB for 8 minutes. DAB was prepared 
by mixing 1 drop of DAB per 1.0 ml of substrate buffer. The reaction was stopped by rinsing 
the slides in PBST then distilled water and thereafter the colour was enhanced with 1% 
copper sulphate for 10 minutes. Haematoxylin was used to counterstain for 2 minutes then in 
Scotts water for 2 minutes for blueing. After rinsing in running tap water for 5 minutes the 
sections were dehydrated in increasing graded alcohols for 10 seconds each, then cleared in 
xylol. The sections were cover slipped using Entellan and left to dry before viewing under a 
light microscope.  
2.12.4 Immunostaining scoring 
A semi-quantitative method was used to evaluate tissue expression of AGP and the mucins. 
Each section was examined by Professor D. Govender at x40 objective and scored as follows: 
<5% non stained cells = 0; 5-25% stained cells = 1+; 26-50% stained cells = 2+; 51-75% 
stained cells = 3+; >75% stained cells = 4+.  
Antibody Antigen Dilutions, incubation 
time  














TRTPAPG sequence in 
tandem repeat region in 
glycoprotein 
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MUC5AC tandem repeat 
sequence 






1:100 (1 hr) Normal gastric 
2° antibody, goat anti-
rabbit, HRPO-linked 
antibody 
 Envision (30 min)  
2° antibody, goat anti-
mouse, HRPO linked 
antibody 
 Envision (30 min)  
Table 2.3: Antibodies and control tissues used in immunohistochemistry. 
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Results and Discussion  
This project aimed to investigate whether alpha-1-acid glycoprotein is a suitable clinical 
biomarker candidate for pre-malignant gastric cancer. Previous results found in our lab 
showed that a PAS positive 55-65kDa glycoprotein associated with albumin was 
reproducibly detected on SDS-PAGE of purified mucins in gastric disease, namely carcinoma 
of the stomach (Mall et al. 1990; Mall et al. 1992). The glycoprotein was also found in the 
gastric juice of patients diagnosed with cancer of the stomach (Mall et al. 2000) and the 
albumin was separable from the glycoprotein on column chromatography. Subsequent studies 
found that this glycoprotein was actually alpha-1-acid glycoprotein (Chirwa et al. 2012) and 
not a fragment of MUC5AC as was previously reported (Mall et al. 1999). The identification 
of the glycoprotein by Chirwa et al (Chirwa et al. 2012) was restricted to a MALDI-TOF 
analysis of 3 spots on a 2D-gels stained with Coommassie Blue (Chirwa et al. 2012). The 
PAS stained spot had not been identified with the possibility of it being another glycoprotein 
other than α-1-acid glycoprotein. 
In this project, we sought firstly to confirm the identity of this glycoprotein. The 
concentration of AGP in the blood plasma of cancer patients was then determined and 
compared with that from healthy controls using ELISA. We correlated the concentrations of 
AGP to the protein levels of MUC1, MUC4, MUC5AC and MUC6. This was done to 
determine whether there was any association between blood AGP levels with gastric mucins. 
This was a study to determine the possibility of there being a combination of markers, namely 
AGP and one or more of the gastric mucins. Immunohistochemistry was also carried out to 
determine protein expression levels of AGP, MUC1, MUC1c, MUC2, MUC4, MUC5AC and 








Chapter three – Mucus purification 
and glycoprotein identification 
3.1 Mucus purification 
 
Crude gastric mucus was collected in 6M GuHCl containing protease inhibitors to prevent 
endogenous proteolysis. The crude mucus was purified twice by isopycnic density gradient 
ultracentrifugation with caesium chloride and 4M GuHCl at a density of 1.39 – 1.40 g/ml to 
remove nucleic acids and protein contaminants.  The protein content was determined by the 
Bradford method (Bradford 1976) and the mucin content by the PAS method of Mantle and 
Allen (1978) (Figure 3.1). The PAS positive peak was collected (density 1.39-1.40g/ml) and 
subjected to another density gradient spin, after which purified mucins were obtained (Creeth 
et al. 1970; Habte et al. 2006). The pool of purified mucins were dialysed overnight against 3 
changes of distilled water and freeze-dried. The purification process is important to allow for 












Figure 3.1: Isopycnic ultracentrifugation profiles of gastric mucus purification.  
Crude gastric mucus was dissolved in 6M GuHCl with 10mM EDTA, 5mM NEM and 1mM PMSF 
pH 6.5 and the density was adjusted to 1.39 – 1.40 g/ml with caesium chloride. Mucins were purified 
by density gradient ultracentrifugation for 48 hours at 40 000 rpm. A: Mucins were PAS positive ( ) 
with a density ( ) between 1.39-1.40 g/ml and some protein (  ) association. B: A second density 
gradient ultracentrifugation was performed and uncontaminated fractions (fraction 3-6) were pooled, 

























































































3.2 Protein separation and glycoprotein staining 
 
3.2.1 1D SDS-PAGE 
The freeze dried samples of the purified mucins were reduced overnight with 10mM DTT 
and blocked with 2.5mM IAA. The proteins were then separated by molecular weight on a 
10% 1D SDS-PAGE and stained with PAS which identifies glycoproteins by staining them 
pink. Figure 3.2 shows 1D SDS gels from patients 1-9. Five of these samples (shown by the 
circles) stained positively for glycoprotein content at approximately 40-50kDa. This 
correlates with previous results found in our laboratory (Chirwa et al. 2012) . Samples 8, 9 
and 10 stained darkly for glycoprotein content indicating high levels of AGP compared to the 




Figure 3.2: 1D SDS-PAGE of purified gastric mucins stained with PAS for glycoprotein 
identification. 
Freeze dried purified mucin samples were reduced with 10mM DTT and blocked with 2.5mM IAA 
overnight then run on a 10% 1D SDS-PAGE at 400V per gel at 20mA for 2 hours with a molecular 
weight marker. Thereafter the gels were stained with PAS to detect glycoproteins. Patients 2, 4, 8, 9 
and 10 (shown by ) stained positive for AGP and could be examined on a 2D electrophoresis gel. 
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3.2.2 2D SDS-PAGE 
3.2.2.1 PAS staining of the 2D SDS-PAGE 
Purified mucus samples from patients 2, 4, 8, 9 and 10 stained positively for a glycoprotein at 
size 40-55kDa. Patient samples 4, 9 and 10 were used for glycoprotein identification as there 
was sufficient freeze dried material to be used for further experimentation. These samples 
were only separated according to molecular weight on the 1D SDS-PAGE thus enabling the 
identification of our protein of interest, they had to be further separated by the isoelectric 
point (pI) using 2D SDS-PAGE. Each sample was precipitated with acetone then resuspended 
in 8M urea and rehydrated on an IPG strip (immobiline pH gradient) (pH 3-10) overnight. 
After undergoing isoelectric focusing in a three stepwise program each sample was run on a 
2D SDS-PAGE and stained with PAS to detect the glycoprotein spot equivalent to the 40-
55kDa glycoprotein of interest. A 12% 2D SDS-PAGE is used to separate proteins according 
to their pI by isoelectric focussing (first dimension) then by the molecular weight by an SDS-
PAGE (second dimension). This enables visualisation of proteins that differ by a single 
charge and can be excised precisely for identification. Figure 3.3 shows sample 4 and 9 
(approximate pI between pH 3 and pH 4) and we observed a pink spot positively identifying 
glycoprotein at approximately 40-55kDa. Sample 10 showed very faint staining which did 
not photograph well. This may be attributed to low amounts of glycoprotein present in the 
sample. The molecular weight marker faded during PAS staining thus a picture of the marker 













                                         
                                        
Figure 3.3: 2D SDS-PAGE of purified gastric mucins stained with PAS for glycoprotein 
identification.  
Patients 4, 9 and 10 that stained positive for glycoprotein content on a 1D SDS-PAGE were run on 2D 
SDS-PAGE gels. The proteins from each sample were precipitated with acetone then resuspended in 
8M urea buffer and one hundred micrograms of each sample was rehydrated on IPG strips overnight. 
The strips underwent isoelectric focusing at 12 000Vh and thereafter were run on a 12% SDS-PAGE 
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3.2.2.2 Coomassie Blue staining of the 2D SDS-PAGE 
The process of separating the proteins two-dimensionally was repeated with samples 4, 9 and 
10 but this time the gels were stained using Coomassie Brilliant Blue. This was done to 
enable the identification of the protein spot of interest for MALDI-TOF-TOF analysis as the 
Coomassie Blue stain is compatible with this process. Figure 3.4a shows the gel stained from 
sample 4 with Coomassie Blue before the spots of interest (shown by the arrow) were excised 
from the gel. A large amount of protein spots are observed on the gel including our protein of 
interest which was highly expressed indicated by the dark staining. Our protein has a size of 
~40-50kDa on this picture which corresponds to the band observed in the 1D SDS-PAGE 
shown in Figure 3.2. 
Figure 3.4b shows the Coomassie Blue stained gel from sample 9 which was also run on a 2D 
SDS-PAGE. This gel differs to the gel shown in Figure 3.4a as there is a reduction in the 
number of overall protein spots observed. The protein of interest is shown with an arrow at 
the size ~40-50kDa with high staining intensity indicating high expression, similar to sample 
4. 
Sample 10, Figure 3.4c again shows a similar Coomassie Blue stained gel to Figure 3.4a and 
3.4b except it has even less protein spots visible. The spot of interest is shown with the arrow 
and it can be observed that though it is the size of our glycoprotein at ~40-50kDa, it stained 









Figure 3.4a: 2D SDS-PAGE of purified gastric mucins stained with Coomassie Blue for protein 
identification in sample 4. 
Sample 4 stained positive for glycoprotein content on a 1D SDS-PAGE and was run on a 12 % 2D 
SDS-PAGE gel. The proteins in the sample were precipitated with acetone then resuspended in 8M 
urea buffer. One hundred micrograms of the sample was rehydrated on an IPG strip overnight. The 
strip then underwent isoelectric focusing up to 12 000Vh and thereafter run on a SDS-PAGE at 130V 
for 75 min. The gel was stained with Coomassie Brilliant Blue to visualise the protein spot of interest 













Figure 3.4b: 2D SDS-PAGE of purified gastric mucins stained with Coomassie Blue for protein 
identification in sample 9. 
Sample 9 stained positive for glycoprotein content on a 1D SDS-PAGE and was run on a 12% 2D 
SDS-PAGE. The proteins in the sample were precipitated with acetone then resuspended in 8M urea 
buffer. One hundred micrograms of the sample was rehydrated on an IPG strip overnight. The strip 
then underwent isoelectric focusing up to 12 000Vh and thereafter run on a SDS-PAGE at 130V for 
75 min. The gel was stained with Coomassie Brilliant Blue to visualise the protein spot of interest 










Figure 3.4c: 2D SDS-PAGE of purified gastric mucins stained with Coomassie Blue for protein 
identification in sample 10. 
Sample 10 stained positive for glycoprotein content on a 1D SDS-PAGE and was run on a 12% 2D 
SDS-PAGE gel. The proteins in the sample were precipitated with acetone then resuspended in 8M 
urea buffer. One hundred micrograms of the sample was rehydrated on an IPG strip overnight. The 
strip then underwent isoelectric focusing up to 12 000VHrs and thereafter run on a SDS-PAGE at 
130V for 75 min. The gel was stained with Coomassie Brilliant Blue to visualise the protein spot of 
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3.3 Glycoprotein Identification 
 
3.3.1 Spot Excision 
After the proteins were separated two dimensionally and stained with Coomasie Brilliant 
Blue, the spot of interest (shown with an arrow, Figure 3.4a-c) was excised. The spot was 
then reduced with DTT, alkylated with IAA and digested with trypsin to produce peptides. 
The peptide digest was analysed on the UltrafleXtreme MALDI-TOF-TOF mass 
spectrometer (Bruker, Bremen). The ions generated were analysed by their mass/charge ratio 
and a list of peptide and amino acid masses (peak lists) were used to search and identify 
proteins in Matrix Science Algorithms.  
3.3.2 Mass Spectrometry Analysis 
Proteins were identified by the probability-based molecular weight search (MOWSE) score 
after they were searched through the SwissProt 2013_01 protein database using the Mascot 
search engine. The protein MOWSE score was calculated as -10
x
Log(P), where P is the 
absolute probability of matching a number of peaks by random chance with a significance 
level of p<0.05. Table 3.1 shows a summary of the identified proteins from sample 4, 9 and 
10 using the above parameters. 
The Mascot search results yielded a histogram for each sample whereby the height of each 
bar reflects the number of protein matches. Sample 4 had an overall MOWSE score of 49 
(p<0.05) and six protein hits identified the protein as alpha-1-acid glycoprotein, the Homo 
sapiens species (shown in Figure 3.5a). Figure 3.5b shows the overall protein sequence 
coverage which was 11%. This reflects the actual measured peptide coverage on the higest 
scoring polypeptide, an α-1-acid glycoprotein (A1AG1_Human PO2736) in the case of 
sample 4 and 9.  
Figure 3.6a shows the Mascot search results run under the same parameters as with sample 4. 
This sample also had six protein hits but had an overall score of 71 (p<0.05) which reflects a 
more confident match than that of sample 4. Figure 3.6b shows that the protein sequence 
coverage was again 11% for the identified protein alpha-1-acid glycoprotein, Homo sapiens. 
Sample 10 was identified as keratin, type II, cytoskeletal 1 shown in Figure 3.7 with three 
protein hits. Obviously this was a false result and keratin contamination may have occurred 
while running the SDS-PAGE and handling the gels, pipette tips and IPG strips thus we 
disregarded this result. 
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Each of the positive results had a p value less than 0.05 which made them significant 
therefore we confirmed previous results in our lab (Chirwa et al. 2012) that the pink spot 
observed when MUC5AC was fragmented (Mall et al. 1999; Mall et al. 1999) was indeed 
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1 MALSWVLTVL SLLPLLEAQI PLCANLVPVP ITNATLDQIT GKWFYIASAF 
51 RNEEYNKSVQ EIQATFFYFT PNKTEDTIFL REYQTRQDQC IYNTTYLNVQ 
101 RENGTISRYV GGQEHFAHLL ILRDTKTYML AFDVNDEKNW GLSVYADKPE 
151 TTKEQLGEFY EALDCLRIPK SDVVYTDWKK DKCEPLEKQH EKERKQEEGE 
201 S 
    
 
 
Figure 3.5: Mascot, a histogram of the probability based score results and protein sequence 
coverage for protein identification from sample 4. 
A: Mascot search results for protein spot (from sample 4) that was excised then run via MALDI TOF 
analysis for identification. The ion score is -10
x
Log (P) where P is the probability that the match 
observed is a random event. Scores > 44 indicates extensive homology (p<0.05). The protein hits 
identified it as A1AG1, Homosapiens; Mass: 23725, Score: 49. B: The matched peptides from our 
protein spot are shown in bold red against the protein sequence of AGP. A protein sequence coverage 







1 MALSWVLTVL SLLPLLEAQI PLCANLVPVP ITNATLDQIT GKWFYIASAF 
51 RNEEYNKSVQ EIQATFFYFT PNKTEDTIFL REYQTRQDQC IYNTTYLNVQ 
101 RENGTISRYV GGQEHFAHLL ILRDTKTYML AFDVNDEKNW GLSVYADKPE 
151 TTKEQLGEFY EALDCLRIPK SDVVYTDWKK DKCEPLEKQH EKERKQEEGE 
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Figure 3.6: Mascot, a histogram of the probability based score results and protein sequence 
coverage for protein identification from sample 9. 
A: Mascot search results for protein spot (from sample 9) that was excised then run via MALDI TOF 
analysis for identification. The ion score is -10
x
Log (P) where P is the probability that the match 
observed is a random event. Scores > 44 indicates extensive homology (p<0.05). The protein hits 
identified it as A1AG1, Homosapiens; Mass: 23725, Score: 71. B: The matched peptides from our 
protein spot are shown in bold red against the protein sequence of AGP. A protein sequence coverage 






Figure 3.7: Mascot, a histogram of the probability based score results for protein identification 
from sample 10. 
Mascot search results for protein spot (from sample 10) that was excised then run via MALDI TOF 
analysis for identification. The ion score is -10
x
Log (P) where P is the probability that the match 
observed is a random event. Scores > 44 indicates extensive homology (p<0.05). The protein hits 
identified it as K2C1, Keratin, Homosapiens; Mass: 66170, Score: 65 which indicates that 
















We sought to identify the glycoprotein that positively stained with PAS previously was AGP 
(Chirwa et al. 2012) using identification by MALDI-TOF-TOF. Firstly we purified the gastric 
scrapes and we observed typical mucin peaks after isopycnic density gradient 
ultracentrifugation with 4M CsCl and GuHCl (Marshall et al. 1978; Carlstedt et al. 1983b). 
The purified mucins were freeze-dried then separated by molecular weight on a 1D SDS-
PAGE. Only samples from patients 2, 4, 8, 9 and 10 (five out of ten patients) stained 
positively for PAS indicating the presence of glycoprotein at approximately 45-50kDa. It is 
unclear why not all mucus scrapes contain this glycoprotein but one may speculate that this 
may be due to various medications that differ from patient to patient during their hospital 
stay. AGP has the ability to bind to basic and neutral drugs such as tamoxifen, a well-known 
cancer drug (Schmid et al. 1973). This may result in differences in the regulation of the 
glycoprotein resulting in down regulation in some patients and up regulation in others. It may 
also be due to inter-individual variation in the expression of the same protein. 
Samples 4, 9 and 10 were then separated two-dimensionally and each stained with PAS and 
Coomassie Brilliant Blue. PAS staining was performed to positively identify the glycoprotein 
(Mantle et al. 1978) . Coomassie Blue staining was used as it is highly compatible with 
MALDI-TOF-TOF MS analysis (Nishihara et al. 2002) which would allow identification of 
the unknown glycoprotein. Samples 4 and 9 has higher staining intensity with both PAS and 
the Coomassie Blue stain indicating high levels of the glycoprotein unlike sample 10 which 
had low staining and thus low expression. We observed a high amount of protein spots in 
sample 4 but observed less in sample 9 and even less in sample 10. This may be attributed to 
medication that patient 6 and 9 were administered or immune suppression corresponding to 
the stage of disease resulting in the decrease in overall protein expression or it may again be 
inter-individual variation.  
Unlike previous work in our laboratory that showed four protein spots after staining with 
Coomassie Blue (Chirwa et al. 2012), we observed one pink PAS spot (Figure 3.3) and one 
Coomassie Blue spot (Figure 3.4a-c) within the pI range pH 3-4 and molecular weight range 
between 45-50 kDa. The reason for the difference in results is unknown but it may be due to 
different glycoforms of AGP due to inter-individual variation or stage of disease (Fournier et 
al. 2000) .  
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The protein spot of interest was excised from the gel, digested with trypsin and peptide 
fragments formed were identified by MALDI-TOF-TOF MS. The protein spot of interest in 
sample 4 and 9 was identified as alpha-1-acid glycoprotein (Homo sapiens). Sample 9 had a 
high protein MOWSE score of 71 compared to sample 4’s score of 49. This may be attributed 
to higher expression of AGP in sample 9. Both results were found to be significant (p<0.05) 
thus we confirmed the previous findings that the pink spot that fragmented with MUC5AC is 
AGP (Mall et al. 1999; Chirwa et al. 2012). This also supported previous findings that the 
protein was N-linked (Mall et al. 1999). Sample 10 was identified as keratin indicating 
contamination had occurred prior to MALDI-TOF-TOF identification.  
The theoretical monoisotopic mass of AGP identified in using the Mascot search engine was 
23.7kDa but the actual molecular weight is 45kDa. Mass spectrometry detects peptides from 
a database and identifies the protein of interest by matching protein sequences. The 
theoretical mass therefore represents the largest peptide that was used to identify the protein 












Chapter four - The development of an 
ELISA for AGP and mucin detection  
4.1 AGP Blood Plasma Concentration 
4.1.1 Healthy Patients compared to Cancer Patients 
Blood samples were collected from gastric cancer patients with irresectable tumours three 
days after a gastrectomy had been performed. The healthy control samples were collected in 
the laboratory from volunteers. The plasma was separated from the blood cells and used in an 
ELISA kit for the detection of AGP. This was done to compare the levels of AGP in healthy 
controls and cancer patients and ascertain if there were any significant differences in AGP 
concentration between the two groups. 
Statistical analysis was performed using the StatPlus package from Analystsoft. Standard 
deviations were calculated as for a sample population. The alpha level of significance was 
chosen at 0.05 and p-values were calculated using standard homo- and heteroscedastic t-tests 














Figure 4.1 shows the AGP concentrations between the two groups. The average concentration 
of AGP in the control samples was 547µg/ml (standard deviation of 142) which was higher 
than the average concentration in the cancer samples which was 336µg/ml (standard 
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Figure 4.1: Human blood plasma concentration of AGP of healthy controls and cancer patients. 
Concentrations of AGP were determined using an alpha-1-acid glycoprotein ELISA kit (Abcam). 
Standards provided by the kit were used to generate a standard curve and this was used to determine 
the AGP protein concentrations in each blood plasma sample from healthy controls and cancer 
patients. The average AGP concentration in the healthy controls was 547µg/ml and in the cancer 








4.2 Determination of Mucin Blood Plasma Levels 
Blood samples were collected as described earlier and the plasma separated by centrifugation. 
A semi-quantitative sandwich ELISA was used to determine the levels of the four gastric 
mucins which are MUC1, MUC4, MUC5AC and MUC6 (measured at OD 405nm). We 
sought to evaluate if there were any detectable levels of each mucin in blood plasma and 
determine any differences between gastric cancer patients and healthy controls.  
4.3 MUC1 Blood Plasma Levels  
4.3.1 Healthy Controls compared to Cancer Patients 
Figure 4.2 shows that MUC1 levels in the plasma followed a similar trend to AGP. The 
control samples were notably higher than the cancer samples. The average absorbance of 
MUC1 in the control samples was 0.324nm, higher than the average of the cancer samples, 




























Figure 4.2: Human blood plasma levels of MUC1 of healthy controls and cancer patients. 
MUC1 plasma levels were determined using a semi-quantitative sandwich ELISA. The levels of 
MUC1 in healthy controls were compared to cancer patients. The average MUC1 absorbance levels in 






4.4 MUC4 Blood Plasma Levels 
4.4.1 Healthy Controls compared to Cancer Patients 
Figure 4.3 shows the blood plasma levels of MUC4 from healthy controls and cancer 
samples. The average absorbance for the controls was 0.265nm which was only slightly 



























Figure 4.3: Human blood plasma levels of MUC4 of healthy controls and cancer patients.  
MUC4 plasma levels were determined using a semi-quantitative sandwich ELISA. The levels of 
MUC4 in healthy controls were compared to cancer patients. The average MUC4 levels in the healthy 












4.5 MUC5AC Blood Plasma Levels 
4.5.1 Healthy Controls compared to Cancer Patients 
MUC5AC absorbance levels are shown below in Figure 4.4. The average absorbance for the 
control samples was 0.301nm which was higher than the average of the cancer samples at 






























Figure 4.4: Human blood plasma levels of MUC5AC of healthy controls and cancer patients. 
MUC5AC plasma levels were determined using a semi-quantitative sandwich ELISA. The levels of 
MUC5AC in healthy controls were compared to cancer patients. The average MUC5AC levels in the 








4.6 MUC6 Blood Plasma Levels 
4.6.1 Cancer Patients compared to Healthy Controls 
Figure 4.5 shows the absorbance levels of MUC6 in controls and cancer samples. We 
observed that MUC6 levels had a similar trend to MUC4 levels. There was a minimal 
difference in plasma levels between the two groups. The average absorbance for the control 
samples was 0.298nm which was slightly higher than the average of the cancer samples at 



























Figure 4.5: Human blood plasma levels of MUC6 of healthy controls and cancer patients.  
MUC6 plasma levels were determined using a semi-quantitative sandwich ELISA. The levels of 
MUC6 in healthy controls were compared to cancer patients. The average MUC6 levels in the healthy 











4.7 Discussion  
 
The concentration of AGP was determined from the blood plasma of healthy controls and 
compared with gastric cancer patients. The average concentration of AGP found in the 
controls was 547µg/ml which was higher than the average of the patients which was 
336µg/ml (p-value=0.00006). This is very surprising as AGP is an acute phase protein which 
increases in response to inflammation which would be present in gastric cancer patients. 
Work done in other laboratories has confirmed this as they observed an increase in AGP 
blood plasma concentration in liver (Kim et al. 2006) breast, lung (Hashimoto et al. 2004) 
and ovarian cancer (Abramson et al. 1982; Duché et al. 2000). Other laboratories also showed 
that patients with malignant disease of the gastrointestinal tract had elevated AGP plasma 
levels compared to healthy controls (Szilvas et al. 1998) . We expected to observe similar 
results but the AGP concentration was found to be higher in the control group. The reason for 
this contradiction in our results is unclear but we speculate that it is probably the advanced 
stage (non-curable resection) of the patients’ disease that leads to immune suppression (Ben-
Baruch 2006). Inflammation aids tumour progression (Coussens et al. 2002) and an immune 
deficiency may result in the down-regulation of cytokines that stimulate production of acute 
phase proteins such as AGP (Daveau et al. 1994) , which would normally combat and reduce 
inflammation (Fournier et al. 2000) .  
Similar to the trend observed with AGP, the MUC1 blood plasma levels detected in the 
control group were higher than in the cancer group (p-value=0.00033). This is in line with 
previous work that observed a decrease in MUC1 in cancer patients. This is due to aberrant 
glycosylation of MUC1 which results in shortened glycoforms that aid in neoplastic 
transformation (Baldus et al. 2004; Bafna et al. 2010). Previous work in our laboratory 
observed an over-expression of MUC1 in gastric cancer tissue (Chirwa et al. 2012).  
The blood plasma levels of MUC4 in both groups were very similar and therefore no 
difference was observed between the two groups (p-value=0.343). MUC4 expression has 
been shown to be up-regulated in gastric tissue of adenomacarcinoma patients (López-Ferrer 
et al. 2000; Senapati et al. 2008) but we observed no significance difference in the blood 
plasma results. This may be the result of low levels of MUC4 in the plasma as it is a 
transmembrane mucin and thus no difference could be detected.   
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The levels of MUC5AC in the blood plasma were measured. We found a statistically 
significant difference between the control group which measured higher levels of MUC5AC 
than the gastric cancer group (p-value=0.023). This result is surprising as MUC5AC is known 
to decrease in gastric cancer (Corfield et al. 2000).  
Similar to MUC4, we observed no significant difference in MUC6 plasma levels between the 
control and cancer group (p-value=0.379). This is also surprising as MUC6 normally 
decreases in gastric cancer and relates closely to the tumour progression (Corfield et al. 
2000).  
The results we observed could be confirmed by an increased sample size of both the control 
and cancer group. This would help determine if the differences observed or lack thereof is 
due to inter-individual differences or changes in protein levels in the blood plasma. This 
would also help ascertain if a mathematical model could be developed and aid in the 
















Chapter five – Determination of 
protein expression in gastric tissue 
5.1 Determination of Immunogenic score in Gastric Tissue using 
Immunohistochemistry 
 
Formalin fixed paraffin wax embedded tissue blocks were obtained from the archives of the 
Division of Anatomical Pathology, National Health Laboratory Service, Groote Schuur 
Hospital (n=4) from patients who had undergone partial or total gastric resection. 
Histochemistry techniques were used to confirm the presence of mucins in the tissue. 
Immunohistochemistry techniques were employed using antibodies against AGP, MUC1, 
MUC1core (MUC1c), MUC2, MUC4, MUC5AC and MUC6 to determine protein expression 
within the gastric tissue. MUC1c and MUC2 were included as changes in expression of 
MUC1c have been observed in gastric cancer tissue. MUC2 was assessed in the tissue as de 
novo expression is observed in gastric cancer tissue. Table 5.1 and Figure 5.1 show a 












Table 5.1: Immunohistochemical score for gastric tissue staining from Patients 3, 4, 10 and 14. 
A semi-quantitative method was used to determine the immunohistochemical score whereby sections 
were examined at (x40 objective) and scored: <5% non stained cells = 0; 5-25% stained cells = 1+; 
26-50% stained cells = 2+; 51-75% stained cells = 3+; >75% stained cells = 4+. 
Antigen Study patient number 
 3 4 10 14 
AGP 0 1+ 0 3+ 
MUC1 0 3+ 2+ 1+ 
MUC1c 0 2+ 3+ 4+ 
MUC2 3+ 0 1+ 0 
MUC4 0 1+ 3+ 0 
MUC5AC 2+ 0 0 3+ 




Figure 5.1: Immunohistochemical score showing differences in AGP and mucin expression in 
gastric tissue. 
Gastric tissue from patients 3, 4, 10 and 14 were each stained separately with AGP, MUC1, MUC1c, 













































5.2 Protein Expression in Gastric Tissue 
 
The expression of AGP, MUC1, MUC1c, MUC2, MUC4, MUC5AC and MUC6 was 
determined using immunohistochemistry techniques. Three types of gastric tissue were 
stained for each antigen, namely: normal gastric, intestinal metaplasia (IM) and 
adenocarcinoma (AD) tissue.  
5.2.1 AGP expression in gastric tissue 
Figure 5.2 shows images of the AGP staining in gastric tissue. Figure 5.2A shows extensive 
staining in normal gastric tissue within the parietal cells. Figure 5.2B shows strong staining 
(score 3+) in the columnar cells surrounding the goblet cells (shown by the arrow) in the IM 
tissue. We only observed staining in one of the three AD patients. Unlike the other two areas 
of gastric tissue, the AD (shown in Figure 5.2C) tissue showed very low staining of AGP, 




















Figure 5.2: Immunohistochemical AGP staining of three different sections of gastric tissue. 
A: Normal gastric tissue showing strong expression in the parietal cells (shown by the arrow). B: 
Intestinal metaplasia tissue showing high expression in the columnar cells (shown by the arrow). C: 










5.2.2 MUC1 expression in gastric tissue 
In Figure 5.3A, there are isolated cells showing MUC1 staining (less than 5%) within the 
normal gastric tissue which is regarded as a negative result. Figure 5.3B shows no staining 
(score of 0) in IM tissue indicating no MUC1 expression. In Figure 5.3C and 5.3D staining is 
seen in two of three AD patients within the cells and glands of AD tissue. Figure 5.3C shows 
high levels of expression in the membranes of the malignant cells resulting in a score of 3+. 
Glandular lumen staining was observed in the AD tissue shown in Figure 5.3D and it was 




















Figure 5.3: Immunohistochemical MUC1 staining of three different sections of gastric tissue. 
A: Isolated cells expressed MUC1 in the normal gastric tissue. B: Intestinal metaplasia tissue showed 
no staining. C: High levels of cellular membrane expression in the tumour cells of the 







5.2.3 MUC1C expression in gastric tissue 
Our results shown in Figure 5.4 indicate that MUC1c expression is similar to the MUC1 
expression observed in Figure 5.3. There was less than 5% staining observed in the normal 
gastric tissue in Figure 5.4A indicating a negative result and a score of 0.  Figure 5.4B shows 
the IM tissue where no MUC1c staining was observed. We observed MUC1c staining in two 
of the three AD patients. The AD tissue shown in Figure 5.4C was scored of 2+. High levels 
of staining were also observed within the lumens of glands of the AD tissue shown in Figure 




















Figure 5.4: Immunohistochemical MUC1C staining of three different sections of gastric tissue. 
A: Minimal staining was observed in the normal gastric tissue B: Intestinal metaplasia tissue showed 
no staining of MUC1c. C: Cellular staining was observed in the adenocarcinoma tissue. D: 







5.2.4 MUC2 expression in gastric tissue 
Figure 5.5 represents MUC2 expression. In the normal gastric tissue, there was no MUC2 
staining (Figure 5.5A). Figure 5.5B indicates low levels of MUC2 expression on the 
membranes of the goblet cells in the IM tissue (shown by an arrow). Two of the three AD 
patients had MUC2 expression. We observed the highest level of cellular expression in 




Figure 5.5: Immunohistochemical MUC2 staining of three different sections of gastric tissue. 
A: No staining was observed in the normal gastric tissue B: Intestinal metaplasia tissue showed focal 







5.2.5 MUC4 expression in gastric tissue 
In normal gastric tissue, shown in Figure 5.6A we observed staining of the cytoplasm of cells 
indicating the presence of MUC4. Focal staining was observed in the areas with IM tissue 
(shown in Figure 5.6B) and this section was given a score of 0. The AD tissue showed very 
high levels of MUC4 cellular staining (one out of three patients) and was given an 




Figure 5.6: Immunohistochemical MUC4 staining of three different sections of gastric tissue. 
A: Staining was observed in the cytoplasm of cells within the normal gastric tissue B: Intestinal 
metaplasia tissue showed very low levels of expression. C: Adenocarcinoma tissue showed high 






5.2.6 MUC5AC expression in gastric tissue 
We observed high levels of MUC5AC staining in the glandular cells of normal gastric tissue 
shown in Figure 5.7A. Figure 5.7B shows no MUC5AC staining in the IM tissue although 
surrounding normal gastric tissue was stained. Staining was observed in two of the three 
cases of adenocarcinoma. Figure 5.7C shows positive staining from one of the cases. High 
levels of MUC5AC membrane staining of the malignant epithelial cells of the glands (score 




















Figure 5.7: Immunohistochemical MUC5AC staining of three different sections of gastric tissue. 
A: A high level of glandular cell staining was observed in the normal gastric tissue B: Intestinal 
metaplasia tissue showed no staining. C: Adenocarcinoma tissue showed high levels of expression in 











5.2.7 MUC 6 expression in gastric tissue 
Similar to Figure 5.7, high levels of MUC6 staining was observed on the membrane of 
glandular cells in normal gastric tissue, shown in Figure 5.8A. No staining was observed in 
Figure 5.8B in the areas with IM tissue but staining was observed in the surrounding normal 
tissue. High levels of staining were observed in the membranes of glandular AD tissue in 





Figure 5.8: Immunohistochemical MUC6 staining of three different sections of gastric tissue. 
A: A high level of glandular staining was observed in the normal gastric tissue B: Intestinal 
metaplasia tissue showed no staining. C: Adenocarcinoma tissue showed high levels of expression in 








The expression of AGP and the mucins in gastric tissue was similar to previous findings in 
our laboratory (Chirwa et al. 2012). AGP expression was largely in the parietal cells of the 
normal gastric tissue. It was highly expressed in the columnar cells surrounding the goblet 
cells of the intestinal metaplasia (IM) tissue. Surprisingly, the adenocarcinoma (AD) tissue 
lacked AGP expression with only one of the three patients staining positively for AGP. This 
may be attributed to high levels of neoplastic transformation in the cells resulting in the 
reduction of the anti-inflammatory proteins such as AGP (Daveau et al. 1994) . Extensive 
changes of normal gastric tissue into IM tissue may also result in a decrease of AGP 
expression and more tests would have to be done to confirm this. The lack of AGP expression 
observed in the AD tissue correlates with our ELISA results. This leads us to believe that 
AGP is actually reduced in gastric cancer patients compared to healthy controls and is not 
overexpressed as previously thought.  
No MUC1 and MUC1c expression was observed in the normal gastric tissue which is 
surprising as it is located in the surface epithelium of neck cells. Likewise, no expression was 
observed in the IM tissue. It is unclear why no expression was observed in the normal tissue 
but the use of a different antibody targeting a different epitope may produce positive results. 
Likewise, this section of normal tissue may have very low undetectable levels of MUC1 and 
MUC1c. 
 High levels of expression were observed in the AD tissue for both MUC1 and MUC1c (two 
of three patients). Expression may not have been observed in one patient as neoplastic 
transformation of MUC1 may have altered the epitopes which would normally be bound by 
the MUC1 antibody.  Our ELISA results indicated that MUC1 plasma expression was higher 
in the healthy controls than the cancer samples but in the tissue we observed the opposite 
result. As MUC1 is a transmembrane mucin, it may be easier to detect in the blood than in the 
deep gland cells where it is normally found in the stomach.  
In line with previous work (Utsunomiya et al. 1998; Gürbüz et al. 2002) , MUC2 expression 
was not observed in the normal gastric tissue but de novo expression was seen in both the IM 
tissue and the AD tissue. Higher levels of MUC2 were observed in the AD tissue and this 
may be a result of malignant transformation compared to the IM tissue.  
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MUC4 expression in normal and diseased gastric tissue was identified in our laboratory using 
immunohistochemistry techniques (Taylor et al. 1998). Similarly, we observed very high 
expression of MUC4 in one patient with AD compared to normal gastric tissue or IM tissue. 
This result does not correlate with the findings from our ELISA. As previously explained 
MUC4 is a transmembrane mucin like MUC1 and may be easier to detect in the blood. In 
gastric cancer, MUC1 and MUC4 often have alterations in their glycosylation pattern 
resulting in shortened glycans which may not be recognised by the antibodies we have used 
in this study (López-Ferrer et al. 2000; Senapati et al. 2008). Regarding the other two AD 
patients, we observed low MUC4 expression in one and no expression in the other which was 
similar to our findings in the normal tissue. This is similar to our ELISA results where there 
was no significant difference between the control and cancer groups.  
High MUC5AC expression was observed in the glandular cells of the normal tissue. Minimal 
expression was observed in the IM tissue which is in line with previous work but we 
observed high levels of expression in one of the three AD patients (Corfield et al. 2001; Mall 
2008). This correlates with our ELISA results in which we observed similar levels of 
MUC5AC in both the control and cancer group. The other two AD patients had no MUC5AC 
staining which may be due to the progress of the disease which causes down-regulation of 
MUC5AC (Corfield et al. 2000) . 
The expression levels of MUC6 between the normal tissue and one of the AD patients 
directly correlates with the levels found in blood plasma. In our ELISA results, we observed 
very similar levels of MUC6 between the control and cancer group. As expected no MUC6 
expression was observed within the area of IM. Interestingly, two AD patients (patient 4 and 
10) had no MUC5AC or MUC6 tissue staining, which may be a result of disease progression 









Discussion, conclusion and future 
work 
According to the American Cancer Society, it is estimated than in the year 2013, 
approximately 1,660,290 new cancer cases were expected in the United States 
(www.cancer.org). Gastric cancer represents a large number of these cases as it is one of the 
highest leading causes of cancer-related deaths worldwide (Ferlay et al. 2010; Jemal et al. 
2011). Gastric cancer has a high prevalence in the Western Cape region of South Africa and 
patients usually present at hospitals when the disease is already at a late stage. At this point, 
there are only a few treatment options available which are not always successful. The 
biomarkers that are currently available, for example carcino-embryonic antigen, are only 
detectable at the late stages of the disease (Fuchs et al. 1995). There is a need for the 
development of a clinical biomarker for gastric cancer which can aid in early detection. This 
could result in the development of a clinical detection biomarker for country wide screening 
for the early detection of gastric cancer. Screening programmes have proved successful in 
countries like Japan where research showed screening with barium X-ray examinations at 
five year intervals could reduce gastric cancer mortality by sixty percent (Fukao et al. 1995). 
Screening using photofluorography (Lee et al. 2006b) and the serum pepsinogen test  (Miki 
2006) in Japan has also been associated with a reduction in the gastric cancer mortality rate.   
Our laboratory showed that a 55-65kDa glycoprotein reproducibly fractionated with gastric 
mucins from crude mucus scrapings and gastric juices from patients with ulceration, 
carcinoma (Mall et al. 1999) and Menetrier’s disease (Mall et al. 2003). As previously 
described, this glycoprotein was identified as AGP (Chirwa et al. 2012) . This project sought 
to confirm these results using crude mucus scrapings from gastric cancer patients as well as 
identifying the PAS positive spot. Three samples were chosen to use for the identification of 
AGP. Two of these samples were positively identified as AGP and unfortunately the third 
sample was contaminated with keratin.  
AGP is an acute phase protein which regulates phagocytic functions and T-cell action 
(Williams et al. 1997). It also primarily acts as an anti-inflammatory and immunomodulatory 
agent (Daemen et al. 2000; Hochepied et al. 2003). AGP has long been considered a possible 
candidate for a clinical biomarker for a range of cancers as it is usually significantly elevated 
in cancers (Fournier et al. 2000). Previous work has shown the successful development of a 
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rapid immunochromatographic strip to test asialo AGP blood plasma levels to diagnose 
hepatocellular carcinoma (HCC) (Lee et al. 2006a). Up to date, there has been no successful 
development of an AGP detection test for gastric disease. AGP has been tested with alpha-
fetoprotein against HCC and the result indicated that the combination of these proteins 
improved sensitivity and increased accuracy in diagnosing HCC (Bachtiar et al. 2009). 
Kundin et. al found that AGP and pre-albumin could be used together for prostate cancer 
screening (Kundin et al. 1981). Consequently work has been done to assess if AGP can be 
used in conjunction with another protein to produce a biomarker. Mucins such as MUC1 and 
MUC4 have shown promise as diagnostic markers in disease (Goydos et al. 1996; Karanikas 
et al. 1997). The aim is to determine an ideal range of concentration of AGP in combination 
with a protein, such as a mucin, and establish a threshold value that would be used to detect 
pre-malignancy. 
We assessed the possibility of AGP as a biomarker for gastric disease by determining its 
concentration in blood plasma as well as in gastric tissue of cancer patients. We observed that 
AGP was decreased (p-value=0.00006) in the plasma of cancer patients compared to that of 
healthy controls. This is surprising as AGP has been found to be elevated in numerous types 
of cancer including gastrointestinal tract malignancies (Szilvas et al. 1998). The majority of 
our sample group had irresectable (late stage) tumours thus we speculate that the reduction in 
AGP was a result of immune suppression (Daveau et al. 1994; Ben-Baruch 2006).  
AGP binds to vitamin B12 (Weinstein et al. 1959) and is extensively involved in drug binding 
thus changes in vitamin B12 levels or the concentrations of compatible drugs could alter the 
detectable concentration of AGP in blood plasma (Fournier et al. 2000). Future work with 
AGP should involve measuring the levels of vitamin B12 and the concentration of drugs in 
each patient. Previous work has found that AGP levels return to baseline two to four weeks 
after surgery (Holley et al. 1984). We measured the concentration of AGP three days after 
surgery which may not represent accurate levels in gastric cancer patients.  
The expression of AGP in adenocarcinoma (AD) and intestinal metaplasia gastric tissue was 
elevated compared to controls. Previous work in our laboratory found high levels of AGP 
expression in cancerous gastric tissue (Chirwa et al. 2012) thus it was surprising that only one 
of the three AD patients stained positively for AGP. This may be attributed to neoplastic 
changes within the tissue resulting in a decrease of AGP expression to undetectable levels 
(Daveau et al. 1994). The differences observed could also be a result of different antibodies 
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used in each study (which may recognise different epitopes). These contradictory results 
make it difficult to come to a conclusion about the correlation of AGP tissue expression and 
its levels in blood plasma in cancer patients.  
In our study, only the clinical information for patient 4 was available for AGP identification, 
determination of AGP expression in blood plasma and gastric tissue. This patient underwent a 
full gastrectomy with a tumour that had metastasised. This may have resulted in immune 
suppression (Daveau et al. 1994) which we mentioned earlier, resulting in the decrease of 
AGP in the blood plasma.  
As mentioned earlier, mucins are also candidates for cancer biomarkers thus we measured the 
plasma levels of MUC1, MUC4, MUC5AC and MUC6 using an ELISA. MUC1 plasma 
levels were lower in the control group than the cancer group (p-value=0.00033) showing a 
similar trend to AGP. AD tissue, where two out of three patients had MUC1 expression 
higher than that of the normal control gastric tissue, showed a similar trend to the MUC1 
blood plasma result. The significant differences observed with AGP and MUC1 make them 
possible candidates to be used together as a clinical biomarker. In our study, we only 
determined the difference of MUC1 levels between healthy controls and that of cancer 
patients, and not the exact concentration. Further work needs to be done to determine the 
concentration of MUC1 in blood plasma to accurately compare it to AGP.  
De novo MUC2 expression was observed within the neoplastic tissue agreeing with 
Utsunomiya’s results (Utsunomiya et al. 1998). It would be interesting to determine if this 
mucin can be detected in the blood plasma of cancer patients and this could be a study for 
future works. MUC4 tissue expression was similar to our ELISA blood plasma results where 
no difference was observed between the control and the cancer group. Interestingly, MUC6 
expression in the gastric tissue of one of the AD patients correlated with our ELISA blood 
plasma results. The other two AD patients showed no MUC5AC and MUC6 staining we 
speculate this may be due to disease progression (Corfield et al. 2000). This result correlated 
with our ELISA for MUC5AC as the levels in the control group were higher than the cancer 
group (p=0.023). 
Further work has to be done to determine the accuracy and sensitivity of AGP as a clinical 
biomarker. The combination of MUC1 and AGP may result in a candidate for a clinical 
biomarker. This study was subject to the number of patients who underwent surgery, but this 
number was low as most of the patients presented with irresectable tumours at the time of the 
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study and only blood samples could be collected from this group. Further work needs to be 
done with a larger sample size of controls and cancer patients with full clinical information to 
allow an accurate determination between AGP in the blood plasma and gastric tissue. AGP 
blood plasma levels need to be measured at regular intervals over a two-four week period to 
determine an accurate range in concentration in cancer patients post-surgery. The levels of 
AGP must also be determined in patients with other gastric diseases during the course of 
infection. Previous work has shown expression of genetic variants of AGP can change 
depending on the type of cancer (Duché et al. 2000). Further work has to be done to 






































Standard curve generated from the reagents provided from the AGP ELISA kit (abcam). This 














REQUEST FOR BLOOD AND GASTRIC SCRAPINGS FOR 




Division of General Surgery 
OMB Groote Schuur Hospital 
UCT Medical School, Observatory 7925  
 
Tel: (021) 406 6168/6227  Fax: (021) 448 6461 
 
 
Please fill in all the information requested: 
 
Folder No.   ___________________________________________ 
 
Sex:   M             F             
 
Date of Birth   Year: ________   Month: ________ Day: ________          Ethnic 
Origin:  _________________________________ 
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